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I. Abbreviations
Terms
AD Alzheimer’s disease
LOAD late onset Alzheimer’s disease
Aβ beta amyloid
APP amyloid precursor protein
APLP1 amyloid precursor protein like protein 1
APLP2 amyloid precursor protein like protein 2
KLC kinesin light chain
PAT1 protein interacting with APP tail 1
APPBP2 amyloid precursor protein binding protein 2
PAT1a protein interacting with APP tail 1a
SNPs single nucleotide polymorphisms
CNS central nerves system
CA1 Cornu Ammonis 1 ( CA1 region of hippocampus)
CA2 Cornu Ammonis 2 ( CA2 region of hippocampus)
CA3 Cornu Ammonis 3 ( CA3 region of hippocampus)
DG dentate gyrus
GFAP glial fibrillary acid protein
GST glutathione S-transferase
siPAT1a small interfering APPBP2/PAT1a
BACE1 β- site APP cleaving enzyme-1
CTF carboxyl terminal fragment
BaSS basolateral sorting signal
PTB phospho tyrosin binding domain
NPTY NPTY motif
PCR polymerize chain reaction
GFP green fluorescence protein
HA hemagglutinin
DIV day in vitro
ELISA Enzyme-Linked Immunosorbent Assay
SH-SY5Y human neuroblastoma cells
CS-GAG chondroitin sulfate glycosaminoglycan
CRD cystein rich domain
Zn/Cu-BD zinc- and copper binding domains
CHD carbohydrate domain
KPI Kunitz-type protease inhibitor domain,
OX-2 MRC-OX2 antigen interacting domain
RIP regulated intramembrane proteolysis
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II. Summary
The physiological function and pathogenic role of the Amyloid Precursor Protein
(APP) and its homologues, Amyloid Precursor Protein like protein 1 and 2 (APLP1,
APLP2), correlate strongly to their subcellular localization. Lines of evidences from
Pimplikar and co-workers showed a kinesin light chain (KLC) like protein, termed
PAT1 (protein interacting with APP tail 1), interacts with both microtubules and the
intracellular domain of APP, in addition, a neuronal function in the microtubule plus
end directed translocation of APP toward the plasma membrane was proposed along
within their study. However neither expression nor functional studies in neuronal
system for PAT1 were done to date.
In this study, we found that the PAT1 sequence exhibits 7 nucleotide exchanges
resulting in 6 non-homologous amino acid substitutions, which are likely due to a
rarely occurring polymorphism in the APPBP2 gene, therefore in this study, APPBP2
was used to perform further investigation on the interaction with APP and APLPs.
Characterization by Northern analysis reveals that APPBP2/PAT1a is ubiquitously
expressed in all tissues examined from Human and Mouse. In situ hybridization and
immunohistochemical analysis clearly show a wide overlap of APPBP2/PAT1a with
APP/APLPs in mouse brain, and is predominantly expressed by neurons.
Further, this study shows the existence of a common complex containing APP family
members and APPBP2/PAT1a in mouse brain. In primary cultured neurons,
APPBP2/PAT1a is partly associated with vesicular membranes among soma and
neurites, bearing APP, APLP1 and APLP2 suggesting that APPBP2/PAT1a is
implicated in the intraneuronal transport of APP/APLPs. The highest degree of
colocalization in neurons was observed for APLP2 in comparison to the other family
members indicating that APPBP2/PAT1a might interact preferentially with APLP2 in
vivo. Moreover, data in this study also showed that the PAT1a protein level affects
APP/APLPs processing and alters Aβ secretion in stably transfected SH-SY5Y cells.
All together, these data reveal the expression pattern of APPBP2/PAT1a in situ in
mouse brain and various tissues among human and mouse, the in vivo interaction of
APPBP2/PAT1a with all APP family members in mouse CNS, and co-distribution in
late secretory pathway in primary neurons. Besides, this study shows that
APPBP2/PAT1a has a regulatory function in APP/APLPs processing and Aβ
production suggesting that APPBP2/PAT1a shall be considered as a alternative
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novel target for analyzing physiological functions of APP family proteins and further,
a potential target for therapeutic approaches to facilitate Aβ production in Alzheimer’s
disease.
                                                                                                                     Introduction
1
1. Introduction
1.1 Alzheimer’s disease
Alzheimer’s disease (AD) is pathologically characterized by neurodegeneration,
intracellular deposition of Neurofibrillary Tangles (NFTs) and production of
extracellular Amyloid Plaques, mainly composed by the hyperphosphorlated tau or a
short peptide, beta-amyloid (Aβ), derived from the Amyloid Precursor protein (APP)
(Selkoe, 1994).  AD lead to progressive loss of cognitive brain functions, deterioration
of the patient’s personality, and finally to the death due to respiratory failure. Patients
with Alzheimer's disease may live for 7 to 10 years after the onset of the disease,
some, however, live for up to 20 years.
The era of molecular biology research in AD started with the identification of the main
constituent of vascular Amyloid and Amyloid (Glenner and Wong, 1984; Masters et
al., 1985). The initial step involves proteolytic cleavages of APP by β- and γ-
secretases, releasing short 40, 42 aa peptides (Aß1-40 and 1-42)(for details, see
chapter 1.2). Polymerization of Aβ and subsequent neuronal deposit lead to the
degeneration of neurons involved in memory and cognition. Aβ deposits also contain
anti-chymotrypsin (ACT), and Apolipoprotein (Apo-E) that may promote Aβ
polymerization (Aksenova et al. 1996; Harr et al. 1996; Ma et al. 1996), although Aβ
deposits or plaques are central to neuropathogenesis and neurodegeneration of AD,
it is still not clear how they affect neuronal functions.
Studies on genetic inheritance of AD found that it is a complex neurodegenerative
disorder predisposed by multiple genetic factors (Cartier-Harlin et al. 2004; Pastor et
al. 2004; Panza et al. 2004). Mutations in APP are known to be associated with
autosomal dominant, early onset familial AD (FAD).  A number of genes encoding
proteins capable of binding to APP have been identified, but their contribution to AD
pathobiology remains largely unclear (King et al. 2004). Conceivably, mutations in
these genes may play a role in affecting AD susceptibility, which appears to be
substantiated by some genetic studies.
Other mutations were found in the Presenilin1 and 2 (PS1, PS2) genes, all of which
are directly involved in the generation of Aβ that support the hypothesis of the
amyloid cascade and in general lead to an earlier age of onset (reviewed in (Annaert
and De Strooper, 2002a).  The main effect of mutations in these genes is the
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overproduction of Aβ42, which was shown to be especially prone to aggregation
(Suzuki et al., 1994). In the pathogenesis of AD, disturbed cellular Calcium
homeostasis ((Mattson and Chan, 2003), oxidative stress, and reactive gliosis were
observed which might play a major role in the disease process (reviewed in (Small et
al., 2001). Moreover, numerous studies found Aß to be toxic to neurons and to
induce apoptosis. Although some researchers now believe that oligomeric Aβ42 is
the crucial agent causing the disease (reviewed in (Selkoe, 2002), the precise
molecular mechanism leading to neurodegenreation in AD remains unclear.  It is also
unclear so far whether Tau hyperphosphorylation or tangle formation is either the
cause or effect of Aß production and deposition. An exciting study in mouse model
systems shows that Aß42 injection in the brain of Tau P301L transgenic mice can
induce formation of PHFs (Gotz et al., 2001), which puts Aß in the front among the
causes of AD pathology.
Recent therapeutic strategies (reviewed in (Janus, 2003) are aiming at preventing Aβ
generation by inhibition of APP cleavage (reviewed in (Dewachter and Van Leuven,
2002), degradation of Aβ with enzymes like IDE (Qiu et al., 1998; Vekrellis et al.,
2000), or immunization with either humanized antibodies against oligomeric Aβ42, or
active immunization with preaggregated Aß peptides (Schenk et al., 1999). Some of
these efforts have already shown promising results (Hock et al. 2002 ; Hock et al.
2003) but no applicable therapy is available to date.
1.2.  Structure, expression, and processing of the Amyloid Precursor   
Protein family
Research in the field of AD was strongly stimulated by the discovery and cloning of a
protein precursor to Aß, the Amyloid Precursor Protein (APP) (Kang et al., 1987).
APP is a Type I transmembrane protein, has one membrane spanning domain, and
belongs to a large protein family which consists in mammals besides APP two
paralogues, the Amyloid Precursor-like Proteins, APLP1 and APLP2 (Suzuki et al.,
1997; Wasco et al., 1992a).
APP is encoded by 18 exons, of which exons 7, 8, and 15 are alternatively spliced.
All eight variants have been shown to exist in vivo and expression of the different
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splice variants is developmentally regulated (Sandbrink et al., 1997). APP resembles
a ubiquitously expressed cell surface receptor with a large ectodomain, a single
transmembrane domain and a short cytoplasmic tail (Kitaguchi et al., 1988; Tanzi et
al., 1988). The major expressed isoforms of APP consist of 695, 751, or 770 amino
acids, all of which are N- and O-glycosylated and transported to the cell surface
through the secretory pathway (Weidemann et al., 1989). APP695 is predominantly
expressed in neurons, while APP751 and 770 are the major species in peripheral
tissues and glial cells (Sandbrink et al., 1994). Alternative splicing by omission of
exon 15 generates a consensus sequence for chondroitin sulfate glycosaminoglycan
(CS-GAG) modification, and the corresponding L-APP Proteoglycans have first been
characterized to be expressed in Leukocytes, but are also found in other peripheral
cells, and to a minor extend in neurons (Sandbrink et al., 1993).
Their are two paralogues of APP in mammals, Amyloid Precursor-like Proteins,
APLP1 and APLP2 (Wasco et al., 1992b; Wasco et al., 1993). Both share high
sequence homology and similar protein domain organization with APP (reviewed in
(Bayer et al., 1999; Coulson et al., 2000a). On the extracellular side, a Cystein rich
domain (CRD) showing Heparin and Collagen binding properties, Zinc- and Copper
binding domains (Zn/Cu-BD) within an acidic region, and a Carbohydrate domain are
conserved. Moreover, the short intracellular domain exhibits the highest degree of
conservation. APP and APLP2 also share an alternatively spliced Kunitz-type
protease inhibitor (KPI) domain, while the OX-2 and the Aβ region are unique to APP.
(Fig.1.1a)
APLP1 is viewed as the ancestral member of the mammalian APP gene family, since
it is closest to the invertebrate homologues (Coulson et al., 2000a) (Fig.1.1b). APLP1
undergoes no alternative splicing and is predominantly expressed in neurons and
some glial cell of the central nervous system (Lorent et al., 1995), which is also
described for Drosophila APPL (Martin-Morris and White, 1990). APLP2 on the other
hand, is alternatively spliced and expressed in a similar pattern as APP (Slunt et al.,
1994). One notable difference between APP and APLP2 is that the major neuronal
form of APLP2 with 763 amino acids contains the KPI domain (Sandbrink et al.,
1997).
In the mammalian brain, all APP family members are widely expressed in a similar
pattern (Crain et al., 1996; Lorent et al., 1995; McNamara et al., 1998; Wasco et al.,
1993). Biochemical analyses have shown presynaptic enrichment for APP (Ferreira
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et al., 1993) and APLP2 (Lyckman et al., 1998), while APLP1 was found to be
specifically localized to the postsynapse (kim et al. 1995).
Fig.1.1: APP family proteins. (a) Schematic domain organization of mammalian
APP members. SP: signal peptide; CRD: Cystein rich domain; Zu/Cu-BD: an acidic
region with Zn-/Cu-binding properties; KPI: kunitz-type proteas inhibitor domain;
OX2: MRC-OX2 antigen domain, are found mostly in non-neuronal glial cells; CHD:
carbohydrate domain; Aβ : β-amyloid domain; ICD: intracellular domain. Brackets
indicate alternatively spliced regions. (b) Family tree consists of identified APP
homologous among 3 different species.
APP is best investigated in regard to its proteolytic cleavage of Aβ, which was found
to be derived from its precursor during normal cellular metabolism (Haass et al.,
1992; Seubert et al., 1993).(Fig.1.2a) In the amyloidogenic pathway, APP is cleaved
by the β- APP cleaving enzyme1 (BACE1) (Hussain et al., 1999; Sinha et al., 1999;
Vassar et al., 1999; Yan et al., 1999), resulting in the release of the soluble β-cleaved
ectodomain (sAPPβ). Subsequently, the remaining C-terminal fragment is further
processed by cleavages at the γ - or ε-sites within the transmembrane region
(Weidemann et al., 2002a), thus setting free of the Aβ peptides (Aβ40, Aβ42) and the
intracellular domain (APPICD). The γ-secretase complex, has been reported
consisting of at least Presenilin, Nicastrin, Aph-1, and Pen-2 (Edbauer et al., 2003;
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Takasugi et al., 2003), is thought to be required for both, γ- and ε-cleavage. The
mechanism of this unusual cleavage within a hydrophobic surrounding is still unclear,
but might be mediated by two aspartic residues present within the transmembrane
region of Presenilin (Wolfe et al., 1999), which may mediate a dual cleavage at the γ-
and ε-sites (Schroeter et al., 2003).
  
Fig. 1.2 Proteolytic cleavage of APP. (a) APP can be cleaved by α -secretase (left,
non-amyloidogenic pathway) or by γ-secretase (upper, amyloidogenic pathway),
resulting in the release of the soluble ectodomain. The APP carboxy-terminal
fragments (C83 and C99, respectively) are substrates for γ-secretase. The γ-
cleavage yields the p3 or Aβ peptides, which are secreted into the extracellular
space, and the APP intracellular domain fragment C59, which is released into the
cytoplasm. (b) Diagram indicates in details, the major and minor cleavage sites of all
secretases among Aβ and Transmembrane (TMD) domains. Two variants of β-
secretase (β1, β2) may cleave APP within the Aβ domain, C99 is generated by both
β1-, β2- cleavages at the same site, and is the majority form of βCTF. The α -
secretase also contains two variants (α-,α’-) that may cleave APP within the Aβ
domain, C83 is generated by α-cleavage and is the major form of αCTF. Both C99
and C83 become a substrate of γ-secretase.
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Alternatively, APP is processed at the α-site, which precludes Aβ generation, and is
therefore called the non-amyloidogenic pathway (Fig.1.2a). Subsequently, proteolysis
of the remaining α-C-terminal fragment by γ-secretase leads to the release of the
APPICD and a short extracellular peptide (p3) (Eggert et al., 2004a; Walsh et al.,
2003a; Weidemann et al., 2002b). The protease activity responsible for α-cleavage is
also not clearly identified so far. Several members of the A Disintegrin and the
ADAM-Metalloprotease family (A Disintegrin and Metalloprotease family),
prominently, MDC-9 (Koike et al., 1999), ADAM-10 (Lammich et al., 1999), and
ADAM-17 (Buxbaum et al., 1998) are described to cleave APP through this α-site,
suggesting a redundant cleavage system.
All APP family members are cleaved in a very similar way, thus represents another
common feature of all APP family members (Fig.1.3), since recent evidence suggests
that APLP1 and APLP2 are cleaved by the same proteases as APP (Eggert et al.,
2004b; Gu et al., 2001; Scheinfeld et al., 2002a; Walsh et al., 2003b).
Fig.1.3 Similar cleavage sites of mammalian APP family. The β-, α-, γ - , ε-
cleavages are found occurring in all three family proteins. Subsequently cleavages by
β - and γ-secretases on APLPs will generate Aβ-like fragements. Subsequently
cleavages by α - and γ-secretases on APLPs will generate p3-like fragements.
Residues indicating in identical colors represent recognition sites for the same
secretases. Red and gray open squares indicate Aβ domain and transmembrane
domain (TMD).
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An interesting point mentioned by several studies, juxta- and intramembranous
cleavage might be a universal signaling mechanism described as regulated
intramembrane proteolysis (RIP) (Brown et al., 2000). Quite a number of
transmembrane proteins have been identified so far to be cleaved also by
Metalloproteases and the γ-secretase complex in a similar manner as APP family
proteins (reviewed in Fortini 2002; (De Strooper, 2003). The most prominent example
is the Notch receptor, a crucial mediator of cell fate decisions and boundary
formation in development ((Selkoe and Kopan, 2003). Notch is initially cleaved by a
Furin-like convertase at the S1-site, creating the heterodimeric, mature receptor. In
contrast to α-cleavage of APP, S2-site cleavage of Notch by a Metalloprotease is
only induced after ligand binding (LaVoie et al. 2003; Kimberly et al 2003), which
results in subsequent γ-secretase mediated processing at the S3- and S4-sites,
similar to γ- and ε-cleavage of APP. The released Notch intracellular domain is
further translocated to the nucleus and can activate transcription of numerous
important genes during development stages. These similarities suggested that
cleavage of APP may also be regulated by ligands, then mediate its nuclear signaling
via the APPICD.  A recent report shows evidences which support this function of APP,
the cleaved APP intracellular domain may form nuclear multiprotein complexes then
regulate the transcription of its own precursor and several other target genes (von
Rotz et al 2004).
1.3. Possible physiological functions of APP family proteins
Over past two decades, numerous biomedical reports have been focused on APP to
approach the role for its pathological feature for AD as well as its physiological
function, but both still remain unclear. Many functions have been attributed to APP
(summarized in (Annaert and De Strooper, 2002a; De Strooper and Annaert, 2000)
and morphological investigations have supplied data for APP taking part in neuronal
cell adhesion (Breen et al., 1991), neurite outgrowth (Allinquant et al., 1995; Qiu et
al., 1995), cell migration (Sabo et al., 2001), fibroblast growth (Ninomiya et al., 1993),
and neural progenitor cell proliferation (Caille et al., 2004; Hayashi et al., 1994;
Ohsawa et al., 2001). Further evidence for the notion that APP is involved in neurite
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outgrowth came from studies with APP-/- primary neuronal cultures exhibiting
diminished neurite branching (Perez et al., 1997).
Studies of APP knockout mice and Drosophila mutants suggested that APP might
play a role in diverse biological processes such as the formation of forebrain
commissures, axogenesis and synaptic differentiation, cell adhesion and neuronal
cell migration, regulation of apoptosis and possibly also in gene regulation (Annaert
and De Strooper, 2002b). However, no obvious structural abnormalities or
physiological deficits in brain was observed in APP knock out mice, suggesting that
in case APP has a crucial neuronal function, it is compensated by other proteins.
Mouse knockouts of APLP1 or APLP2 are viable with very subtle deficits as well,
whereas combinations of APLP2 -/- and APP -/- or APLP1 -/- are lethal shortly after
birth (Heber et al., 2000; von Koch et al., 1997). Interestingly, APP and APLP1
double knockout mice are viable with no obvious phenotype (Heber et al., 2000)
suggesting APLP2 as the essential family member during development. However,
the causes of death are still unknown.
Biochemical analyses have shown that APP exhibits properties as a cell adhesion
protein, since it is strongly associated with extracellular matrix components (Small et
al., 1992).  The ectodomains of APP was shown to bind Heparin (Caceres and
Brandan, 1997; Clarris et al., 1997; Multhaup, 1994; Multhaup et al., 1995;
Williamson et al., 1995) and Collagen (Beher et al., 1996) with high affinity, and form
complexes with secreted Cerebroglycan that could be isolated from rat brain
(Williamson et al., 1996).
Besides, one study showed that F-spondin, a secreted signaling molecule implicated
in neuronal development and repair, binds to the conserved central ectodomains of
APP and may inhibit beta-secretase cleavage of APP proposing that F-spondin may
be an endogenous regulator of APP cleavage (Ho et al,. 2004). The ectodomains of
APP family proteins were also shown to bind Zinc (Bush et al., 1994) and Copper
(Simons et al., 2002), and APP is able to reduce bound Cu2+ to Cu+(Multhaup et al.,
1996).
Structural study of the N-terminal APP Heparin- (Rossjohn et al., 1999) and Copper-
binding domains (Barnham et al., 2003) shows corroborating a growth factor- or
receptor-like function.  An interesting study reported that Fibulin-1 (Ohsawa et al.,
2001) which contains repetitive Ca(2+)-binding EGF-like elements, binds to APP at
above mentioned growth factor-like domain, forms fibulin-1/sAPP heteromer that
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may modulate the neurotrophic activities of APP. Another report showed, APP forms
cellular cis-Dimers (Scheuermann et al., 2001), which is reminiscent of classical
receptor dimerization described for the EGF receptor (reviewed in (Schlessinger,
2002). APP-dimers could be crosslinked in cell lysates and dimerization seems to be
mediated by the Collagen binding domain, and possibly also by the Carbohydrate
domain (Beher et al., 1996; Scheuermann et al., 2001). However, it is unclear
whether dimerization of APP is essential for ligand binding, and if dimerization could
influence the distribution of APP.
  
Fig 1.4: Schematic overview of the Intracellular adaptor proteins of APP. PAT1
and APPBP2 are thought to be proteins from the same gene products, and have
been identified interacting directly with APPICD via BaSS (green). G0 protein has been
identified to bind APPICD through the G0 binding region (purple). Fe65, X11, Dab-1
and JIP1/2, and Numb have all been identified to bind APPICD to the NPTY motif (light
orange). Both KLC1/2 and APPBP1 have been identified to bind APPICD as well, but
the specific region has not been clarified yet. Note BaSS is located right adjacent to
the TMD, at the beginning of APPICD.
An important perquisite for proper function of APP/APLPs is the correct subcellular
localization, which was shown to depend on three different domains: the
juxtamembraneouse extra- and intacellular domain, including the Aβ domain (Tienari
et al., 1996) and Tyrosine containing BaSS (Haass et al., 1995), respectively, as well
as the NPTY-motif, located near to the carboxy terminus(Fig.1.4). The NPTY motif is
essential for proper endocytosis of APP/APLPs and it mediates binding to multiple
protein partners carrying a phospho tyrosin binding (PTB) domain which play
essential roles in signal transduction and protein transport ((King and Scott Turner,
2004). The juxtamembraneouse extracellular domain, including the Abeta domain
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was reported as an essential motif for axonal sorting of APP (Tienari et al. 1996),
whereas the BaSS was shown to mediate basolateral sorting of APP (De Strooper et
al. 1995) in epithelial cells. According to the sorting paradigm of Dotti and Simons
(Dotti and Simons, 1990), these two domains might mediate sorting in different
directions in neuronal cells as well.
As to date, Disabled-1 (Dab-1) (Homayouni et al., 1999; Howell et al., 1999;
Trommsdorff et al., 1998), Shc (Russo et al., 2002; Tarr et al., 2002), JIP1 (Matsuda
et al., 2001; Scheinfeld et al., 2002b), X11 (McLoughlin and Miller, 1996; Tomita et
al., 1999; Zhang et al., 1997), and Fe65 (Borg et al., 1996; Duilio et al., 1998; Fiore et
al., 1995; McLoughlin and Miller, 1996; Trommsdorff et al., 1998; Zambrano et al.,
1997) have been described to interact with the NPTY motif of at least one APP family
member (Fig.1.4). Binding of some of these intracellular adaptor proteins have been
shown to affect the processing of APP. Prominently, X11 and Fe65 seem to have
antagonizing effects. While X11 can stabilize the full length APP protein upon
overexpression. (Borg et al., 1998; Mueller et al., 2000; Tomita et al., 1999), Fe65
expression and binding seems to increase APP processing and secretion of Aβ
(Sabo et al., 2001), suggesting both interaction partners can influence intracellular
transport and function in a distinct way. Intriguingly, Fe65 and APP colocalize with
β1-Integrins at focal complex adhesion sites, and increase cell motility upon
overexpression (Sabo et al., 2001).
An additional proposed function of the APPICD implies nuclear translocation together
with Fe65, where a complex of APPICD, Fe65 and TIP60, a Histone-Acetyl-
Transferase, exhibits transcriptional activity (Cao and Sudhof, 2001). Similar results
have been obtained for the APLP1 and APLP2 intracellular domains (Scheinfeld et
al., 2002a; Walsh et al., 2003b), while APP might additionally activate transcription in
complex with JIP-1 (Scheinfeld et al., 2003). In vivo evidence for transcriptional
activation of the kai1 gene by the APPID/Fe65/Tip60 complex corroborates a function
of APP in nuclear signaling (Baek et al., 2002), although there is still some
controversy in regard to nuclear translocation of the APPICD (Cao and Sudhof, 2004;
Kinoshita et al., 2002; Muresan and Muresan, 2004).
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1.4. APP functions as a cargo receptor, interacts with Kinesin-I in
neurons
In neurons, APP is transported within axons by fast anterograde axonal transport
from the neuronal cell bodies to the distal never terminals (Koo et al., 1990; Sisodia
et al,. 1993). Antisense inhibition using oligonucleotides complementary to kinesin
heavy chain coding sequences in hippocampal neurons suggested that axonal
transport of APP requires the microtubule-dependant motor protein kinesin-I (Ferreira
et al., 1993: Amaratunga et al., 1995; Yamazaki et al., 1995; Kaether et al., 2000). A
study using coimmunoprecipitation, sucrose gradient, and direct in vitro binding
assay demonstrated that APP forms a complex with the kinesin-I by binding directly
to the TPR domain of the kinesin light chain (KLC) subunit (Kamal et al., 2000).
Kinesin-I, was the first member of the kinesin superfamily to be identified (Brady et
al., 1985; Vale et al., 1985) and is responsible for ATP-dependent movement of
vesicular cargoes within cells (reviewed in Goldstein and Philip, 1999; Goldstein and
Yang, 2000; Kamal and Goldstein, 2000). Kinesin-I is composed of two components,
kinesin heavy chain (KHC) and kinesin light chain (KLC), KLC associates with KHC
and tethers membrane vesicles containing a subset of proteins that are transported
along the axon from the neuronal cell body to nerve terminals. In addition, within the
same study of (Kamal et al., 2000), the author also reported that association of APP
with microtubules and axonal transport of APP is greatly decreased in a gene-
targeted mouse mutant of the neuronally enriched KLC1 gene, thus led to the
proposal of that, one of the normal functions of APP may be as a membrane cargo
receptor for kinesin-I and that KLC is important for kinesin-I-driven transport of APP
into axons.
Complementary studies revealed that deletion of the app-like gene (appl) in the fruit
fly, or overexpression of human APP constructs that contained APP or APLP2
cytoplasmic domains, caused aberrant accumulation of transported membrane
vesicles within axons (Gunawardena et al., 2001). This phenotype has also been
observed in flies that lack kinesin or dynein, a microtubule-activated ATPase that
transports membrane vesicles from neuronal dendrites back to the cell body.
Later, a report showed that BACE1 and PS1 are found in membrane vesicles
transported along the axons of peripheral and central mouse neurons, and this
transport requires APP (Kamal et al., 2001). This study provides complementary
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evidence that APP functions as a Kinesin-I membrane receptor to transport an
axonal membrane compartment containing the neurotrophin receptor TrkA, the
synaptic vesicle-associated phosphoprotein synapsin 1, and the growth-associated
protein GAP-43, which regulates cytoskeletal dynamics in neuronal growth cones.
Collectively, with reference to above findings would imply that APP is the receptor for
Kinesin-I, however, there is no evidence as yet that APP and KLC directly associate
with each other in vivo. On the other hand, the observation that transport of BACE1,
PS1, KHC, and KLC still occurs, albeit at lower levels, in the APP-deficient mice,
suggesting that APP is unlikely the only cargo receptor for Kinesin-I. It is possible
that axonally transported APLP1 and APLP2 (Kamal et al., 2001) might compensate
for APP.  Moreover, still the evidence of direct binding of APP and KLC can not
exclude the existence of indirect binding via adaptor proteins, such as JIPs, It has
been shown that APP may bind JIPs via its PTB domain (Matsuda et al., 2001;
Scheinfeld et al., 2001), JIPs may bind to the TPR domain of KLC (Verhey et al.,
2001) and might mediate APP transports in cells (Fig.1.5).
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(Sangram S. Sisodia. (2002) Science, 295, 805-807)
Fig.1.5: The association of APP with kinesin-I. Membrane vesicles containing
protein cargo are transported along axons from the neuronal cell body to nerve
terminals. This process is dependent on kinesin-1, which consists of two kinesin
heavy chains (KHCs) (blue) and two kinesin light chains (KLCs) (orange). The KLCs
are bound to axonal microtubules via the microtubule- and ATP-binding domains of
KHC. There are two possible ways in which membrane vesicles containing cargo can
associate with kinesin-1. In the first, APP binds directly to the tetratricopeptide (TPR)
domains of KLCs, thus linking membrane vesicles to microtubules. In the second,
APP or APP carboxyl-terminal fragments could bind to the phosphotyrosine-binding
domains of the JIP scaffolding protein family. The JIPs in turn could then bind to the
TPR domains of KLC via their carboxyl-terminal regions. In addition, phosphorylation
of Thr668 in the APP cytoplasmic domain might serve to modulate the interaction of
APP and APP carboxyl-terminal fragments with the KLCs or JIPs.
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1.5. Discovery of PAT1 and its relationship with APP
Using yeast two-hybrid screen with the APP-BaSS (amino acid sequence in one
letter code KKKQYTSIHHG) fused to the DNA-binding domain of LexA as a bait,
Pimplikar an co-works (Zheng et al., 1998) isolated a positive clone from a HeLa
cDNA library, and reported it as a kinesin light chain (KLC) – like protein, termed in
their article as protein interacting with APP tail 1 (PAT1). Their study showed that,
PAT1 interacts with the APP - BaSS (Fig.1.4) but binds poorly when the critical
tyrosine is mutated and does not bind the tyrosine - based endocytic signal of APP.
Biochemical assay shows that, PAT1 protein sequence consists of 585 amino acids
with a calculated molecular mass of 66.9 kDa and a predicted isoelectric point of 6.9.
The N-terminal and C-terminal regions are predicted to form globular structures and
a stretch of 35 amino acids is predicted to form 5 heptad repeats that are likely to
form a coiled coil, and four imperfect tandem repeats are found toward the C-terminal
end of the protein (Fig.1.6a). Reference from their search of public data bases, PAT
1 shows a significant homology to kinesin light chain which is a component of the
plus - end directed microtubule - based motor involved in transporting membrane
proteins to the basolateral surface in epithelial cells. The region of maximum
homology between PAT1 and KLC contains the characteristic four 42-amino acid
imperfect tandem repeats conserved in all species of KLCs. Several residues in each
repeat are conserved between the KLC and PAT1 sequences. However, the first
repeat contains two insertions of 7 and 11 amino acids.
Further characterization of PAT1 shows that it is a cytoplasmic protein, associates
with membranes as tested by ultracentrifugation (150,000Xg) and reconfirmed by
chemical cross-linking approach. This study also showed that PAT1 may
cofractionate with APP-containing vesicles as examined by sucrose density gradient
floatation, and bind to microtubules as tested by microtubule binding assay (McIlvian
et al., 1994). Cotransfection of PAT1 with a reporter protein shows that PAT 1 is
functionally linked with intracellular transport of APP which leads to the proposal,
PAT1 is involved in the translocation of APP along microtubules toward the cell
surface. (Zheng et al., 1998).
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Fig. 1.6: Schematic representation of putative motifs present in PAT1.  (a) PAT1
consists of 585 amino acids, a stretch of 35 amino acids was predicted to form a
coiled coil domain and 4 KLC-like imperfect tandem repeats were found toward the
C-terminal end of the protein. Simplified schematic representation of KLC structure is
given to compare the structural similarity proposed by (Zheng et al.,1998). (b) PAT1
were predicted to contain several protein-protein-interacting motifs, including two
leucine zippers, a cyclin box, a "LXXLL" motif (NR-Box), 4 tetratricopeptide repeat
(TPR) domains that also present in kinesin light chain, a proline (P), glutamate (E),
serine (S), and threonine (T) rich (PEST) protein-degradation domain, multiple
putative nuclear localization signals and leucine-rich nuclear export signals(NESs).
Note, in (b), the predicted coiled coil region is missing and the TPR domain are
completely shifted in comparison to (a).
Second study of PAT1 published by the same group shows that overexpression of
Cγ-59 derived from APP causes disappearance of PAT1 from the nucleus and
induces its proteosomal degradation. Treatment of cells with lactacystin, an ubiquitin-
proteasome inhibitor, prevents PAT1 degradation and retains its nuclear localization
whereas Cγ-57, a minor product of γ-cleavage, is only marginally effective in PAT1
degradation (Gao et al. 2001).
In this study, PAT1 was characterized as a nucleocytoplasmic protein in contradictory
to their previous study. They claimed the failure to detect PAT1 signal in the nucleus
in the first study presumably was because the tyramide signal-amplification system
did not gain access to the nuclear compartment.  Further and more detailed
sequence analysis predicts the presence of several protein-protein-interacting motifs
(Fig.1.6.b). Their predication in this study of PAT1 protein structure showing in
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schematic ideograph represent two leucine zipper motifs generally involved in
dimerization and also in binding DNA (Alber et al. 1992), a putative cyclin box found
in many cyclin-dependent kinases, a "LXXLL" motif (NR-Box) that is present in
transcription coregulators (Heery et al. 1997), four tetratricopeptide repeat (TPR)
domains that are also present in kinesin light chain (Gindhart et al, 1996), and a
proline (P), glutamate (E), serine (S), and threonine (T) rich (PEST) protein-
degradation domain (Rechsteiner et al, 1996) at the extreme C terminus that is
common in regulatory proteins with high turnover rates. Further they reported
evidence for multiple putative nuclear localization signals (NLS) and leucine-rich
nuclear export signals (NESs) (Mattaj, et al, 1998). However, the prediction of
domains reported in this second study is another contradictory statement to their
previous study. They included several novel domains and motifs, and hence changed
the putative positions of the TPRs completely. The four imperfect KLC-like tandem
repeats were predicted to locate in between aa 352 and aa 537 (1st: aa352-411; 2nd:
aa412-453; 3rd: aa454-496; 4th: aa497-537) in the first study, but the four
tetratricopeptide tandem repeats  (TPR) were indicated to be located at 1st: 288-321;
2nd to 4th(without specifying): aa429-547 (Fig.1.6ab) in the second study of PAT1.
1.6.  APPBP2/PAT1a versus PAT1 and Ara67
The name APPBP2 (Amyloid precursor protein-binding protein 2) first appeared in
(Monni et al. 2001), which was found in breast cancer cell lines to be one of limited
number of highly expressed genes on locus 17q23, a common region of amplification
in breast cancers with poor prognosis. Later it was found to exhibit significantly
elevated expression in ovarian clear cell adenocarcinomas (Hirasawa et al. 2003)
and Neuroblastomas (Saito-Ohara et al. 2003).   
Homology search through NCBI GeneBank revealed its synonyms are PAT1,
HS.84084, and KIAA0228. Selected protein identity found to be 26.95% among
166aa to mouse Kinesin light chain 1 (mKLC1) (M. musculus sp:O88447), and
24.68% among 228 aa to rat Kinesin light chain C (rKLC C) (R. norvegicus
pir:C41539 - C41539) (http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&CID=84084 ).
Summary in the GeneBank describes: “The protein encoded by this gene interacts
with microtubules, is functionally associated with beta-amyloid precursor protein
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transport and/or processing. The beta-amyloid precursor protein is a cell surface
protein with signal-transducing properties, and it is thought to play a role in the
pathogenesis of Alzheimer's disease. This gene has been found to be highly
expressed in breast cancer. Multiple polyadenylation sites have been found for this
gene“.
Interestingly, among all research articles (Monni et al. 2001; Hirasawa et al. 2003;
Saito-Ohara et al. 2003) under the name of APPBP2 that can be found through
public resources, neither any binding assay nor any evidence of its interaction with
APP were mentioned. In the first appearance (Monni et al. 2001) of such a protein
named APPBP2, the author used a combined name as “PAT1/APPBP2” to represent
the newly identified gene within their approach, and the listed reference linked to the
putative function of APPBP2 is the publication of PAT1, which indicated that PAT1
and APPBP2 were thought to represent the same gene products.
While cloning PAT1, we met difficulties to match the sequences in the data base.
Surprisingly, among all independent clones, we consistently found seven nucleotide
exchanges, resulting in six amino acid substitutions (F296L, K325R, A337A, S340C,
L354V, P369R, N542K,). A sequence (APPBP2 cDNA: NM_006380; aa:
NP_006371.2) completely identical with the sequence we amplified from the human
brain cDNA library, is annotated to carry these nucleotides as 7 Single Nucleotide
Polymorphisms (SNPs) in contrast with PAT1 (Fig.3.1.2). Publications of PAT1 are
found to be listed under the references of APPBP2 to represent traceable proposed
function. (see  http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=18104961).
Sequence analysis of ESTs that are available in the data base, also exhibiting the
same 7 SNPs as well, indicate that APPBP2 is the major variant of this gene
products.
Since  we were  unable to match PAT1 but the APPBP2  sequences with the
products a mplified  from human brain cDNA library, so that the cDNA carries the
same coding  sequence as APPBP2 is used in this study.  We proposed to name
newly the target gene product PAT1a in our study is because in our further works on
APPBP2, we found the functional similarity on APPBP2 as to PAt1, however there
was neither characterization nor functional study were ever done for APPBP2. We
think this new name PAT1a should clearly reveal the truth for genetic difference and
our findings of functional similarity in between APPBP2 and PAT1.
Interestingly to mention, an androgen receptor associated protein Ara67 was
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described to be 99,6% homologous to PAT1 (Zhang et al. 2004), likely represent an
additional variant of APPBP2/PAT1a, suggesting a high polymorphism in this gene.
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2.  Aim of this study
An important prerequisite for proper function of APP/APLPs is their correct
subcellular localization, which depends on three different domains: firstly, the
juxtamembraneous extracellular region encompassing the Aβ domain is essential for
axonal sorting of APP (Tienari et al., 1996). Secondly, the juxtamembraneous
intracellular domain, including the tyrosine containing basolateral sorting signal
(BaSS), mediates basolateral sorting (Haass et al., 1995). Thirdly, the C-terminal
NPTY-motif is essential for endocytosis of APP/APLPs, as well for binding to multiple
interaction partners carrying a phosphotyrosine binding (PTB) domain (King and
Scott Turner, 2004). In epithelial cells, sorting of APP and APLP2 to the basolateral
surface depends on the presence of a BaSS in their cytoplasmic domain, and
mutation of the tyrosine residue on the BaSS of APP results in nonpolarized transport
of APP in NDCK cells (Haass et al., 1995). According to the sorting paradigm of Dotti
and Simons (Dotti and Simons, 1990), the Aβ domain and the BaSS may mediate
sorting to different subcellular compartments.
To date, the only indentified partner interacting with the BaSS of APP is PAT1
(protein interacting with APP tail 1).  PAT1 has been reported to interact with both
microtubules and the BaSS of APP, thus led Pimpliker and co-workers proposed that
PAT1 is involved in the translocation of APP along microtubules toward the cell
surface (Zheng et al., 1998).  However these authors reported only low affinity
binding of PAT1 to APP in number, and neither neuronal function of PAT1 nor the
existence of in vivo interaction have been tested.  Different evidences have shown
that both APLP1 and APLP2 share high sequence homology and similar protein
domain organizations with APP (Coulson et al., 2000b), have similar subcellular
localization ,and are cleaved in a very similar way (Eggert et al., 2004a). It is
therefore reasonable to assume that PAT1 might interact with these 2 family
members as well.
The aim of this study is to investigate if PAT1 is expressed in central nerves system,
then to compare its localization with APP family members and seek in vivo evidence
of interactions with each family members. Hence, to investigate whether regulation of
this carboxyl terminal interaction partner may affect subcellular trafficking or influence
the processing in neuronal cell system. We believe this study will help to gain new
knowledge to distinguish the similarities and diversities in the APP family proteins.
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This will help to clarify the physiological functions and the pathogenic role of APP,
which might contribute new insights to design new therapeutic approaches for AD.
(Fig.2).
  
Fig.2: Ideograph of the aim of this study. Based on the studies of PAT1, that was
reported as a Kinesin light chain like protein and binds to APP, APP has been shown
undergoes fast axonal transport via Kinesin-I. This study will aim on solving the
questions marked in red. First, if the binding of PAT1 and APP may be found in vivo
and if this affects APP transport and proteolytic cleavages. In parallel, to find if PAT1
also interacts with APP mammalian homologous APLP1, APLP2, and if the
interaction affects similarly as to APP.
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3. Results
3.1.    PAT1 is a rare genetic variant of APPBP2/PAT1a
3.1.1.    Alignment result of PCR products
Difficulties occurred while matching clones of PCR product to PAT1 sequence. After
discard many clones, we started to doubt that the expected PCR product length is
1758bp, and we found that all of our clones carry at least 7 mutations, which in
nowadays is an unexpectedly rare case based on the known quality of biotechnology.
We thus aligned all available sequencing results to PAT1 sequence and found 7
common mutations occurred in all clones.
Fig.3.1.1: Schematic representation of sequencing alignment. Different
sequences of clones resulted from amplification products of PAT1 were aligned by
SeqMenII (DNAstar, LASERGENE). Characters in red color indicate the positions of
mutated nucleotides aligned to PAT1. Numbers of positions indicate in red color
represent mutations that occurred in all clones. Nucleotide change at position1011
will result silent mutation, others will result amino acids changes while translation.
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3.1.2. Genetic database analysis of PAT1, APPBP2/PAT1a and related ESTs
Comparison of the PAT1 cDNA sequence (AF017782) with the APPBP2 cDNA
(NM_006380) or the genomic sequence (APPBP2; LocusID: 10513) reveals that
PAT1 contains seven nucleotide exchanges (888c→g, 974a→g, 1011c→a,
1019c→g, 1060c→g, 1106c→g, 1626c→g), resulting in six non-homologues amino
acid substitutions (F296L, K325R, S340C, L354V, P369R, N544K, A337A)
(Fig.3.1.2). Six of the seven nucleotide exchanges are annotated as single nucleotide
polymorphisms in the database, indicating that PAT1 is a variant of APPBP2. We
wanted to amplify the coding region of the PAT1 from a human brain cDNA library
but surprisingly found in eight independent clones consistently matching the
sequence of APPBP2 among those positions of SNPs, but not the sequence of
PAT1, suggesting that the variant PAT1 might occur at low frequency. To test how
frequent the SNPs occur, we analyzed 53 ESTs covering the region of PAT1 cDNA
containing the nucleotide exchanges. Unexpectedly, all tested EST sequences were
identical with the sequence of APPBP2, but none was equal to PAT1, suggesting that
the PAT1 sequence, used in previous analysis (Zheng et al.,1998; Gao et al, 2001)
carries 6 non-homologous amino acid exchanges and likely represents a very seldom
variant of APPBP2 in human brain. For simplification, and as no characterization
experiments were done for APPBP2, we think it is more suitable to rename it as
PAT1a.
Based on computational analysis of APPBP2/PAT1a, using different programs to
predict protein domains (coils, REP, PROSITE (http://www.expasy.ch)), we found
significant predictions for one tetratricopeptide repeat (TPR) (aa 429-462), three
TPR-like motifs (aa 288-321, 471-505, 514-547), and weak evidences for a coiled
coil domain (aa 257-273). These data are widely consistent with the domains of
PAT1 predicted by Zheng and coworkers (Zheng et al., 1998) (Fig.1.5a), whereas we
found no evidence for the existence of a PEST domain, Leucin-zipper and putative
nuclear localization sequences, as postulated by Gao and co-workers (Gao at al.,
2001) (Fig.1.5b), which might be explained by the non homologous amino acid
exchanges in the PAT1 sequence (Fig.3.1.2).
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Fig.3.1.2: Schematic representation of the genomic structure, cDNA, and
protein organization of APPBP2/PAT1a in comparison to PAT1
(a.)The human APPBP2/PAT1a cDNA has a length of 6468 bp and is genomically
represented by 13 exons (I-XIII). Exon boundaries within the coding region of the
PAT1a cDNA (1758 bp) are marked. The nucleotide exchanges present in the PAT1
sequence are indicated. Those nucleotide exchanges present in PAT1, which are
annotated as single nucleotide polymorphisms (SNPs) in the genomic sequence are
marked by an asterisk. The accession numbers and relative positions of five ESTs
that correspond to the PAT1a sequence are shown. (b.) Protein structure of human
APPBP2/PAT1a predicted in this study. The amino acid substitutions in the sequence
of APPBP2/PAT1a are given. The positions of predicted helix-loop-helix motifs with a
significant homology to tetratricopeptide like repeats (TR) are indicated.  Characters
indicate in purple or red colors representing hAPPBP2/PAT1a and PAT1 nucleotides
or amino acid sequences.
3.2. Northern Analysis of APPBP2/PAT1a in various Human and
Mouse tissues
Neuronal function in subcellular transport of APP for PAT1 was proposed (Zheng et
al. 1998). However, no study addressing its expression in brain has been performed.
To clarify whether APPBP2/PAT1 is expressed in mammalian brains, Northern
analysis with a randomly 32P-labelled oligonucleotides and full-length cRNA probes
directed against the coding sequence of APPBP2/PAT1a were performed. Since
PAT1 and APPBP2/PAT1a are 99% identical,this analysis will detect both transcripts.
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Both probes recognized mRNAs with a length of 6.5kb, 4.3kb and 2.3kb in all tissues
examined. The transcripts detected at 6.5kb perfectly matched the predicted size of
the PAT1a cDNA (6,48kb), which was the same as observed by (Nagase et al. 1996)
who detected ubiquitous expression of KIAA0228 as an approximately 6.5-kb
transcript.  Some lower bands at 6.2 kb (mouse), 4.3kb and 2.3kb (human and
mouse) might represent alternatively spliced transcripts, since sequence analysis of
the full-length cDNA revealed no sign of alternative initiation on this gene. Our data
also revealed high levels of APPBP2/PAT1a transcripts during early development.
Interestingly, in the course of development, some variations in the expression level
were observed for the longest PAT1a transcript, whereas the expression levels of the
4.3kb transcript remained unchanged. In brief, the Northern data show that the
APPBP2/PAT1a gene is expressed in multiple tissues, including brain, and might be
differentially spliced in the different tissues and during development.
3.2.1. Expression of PAT1a/APPBP2 transcripts in multiple human tissues
The initiating experiment of this study was to check the expression of
APPBP2/PAT1a in humam, Using APPBP2/PAT1 32P-labelled full-length cRNA
probes (hydrolized to~500bp) hybridizated to the human MTNblot (Clontech), the
result shows that the APPBP2/PAT1a transcripts may be detected with most
pronounced levels in brain, placenta, and kidney in human.
Fig.3.2.1: Northern analysis of APPBP2/PAT1a transcripts in multiple human
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tissue. The transcripts detected at ∼6.5kb perfectly matched the predicted size of the
APPBP2/PAT1a cDNA (6,48kb). The lower bands at 4.3 kb and 2.3 kb might
represent alternatively spliced transcripts. (H.: heart; B.: Brain; Pla.: placenta; L.:
Lung; Liv.: liver; S.M.: skeleton muscle; K.: kidney; P.: pancreas.) Some lanes with
higher background were adjusted to reveal comparable information. Rehybridization
with a random 32P-labelled cRNA probe derived from human ß-actin cDNA confirmed
that comparable amounts of various mRNA were loaded (lower panels).
3.2.2. Expression of APPBP2/PAT1a transcripts in multiple mouse tissues
Considering for research analysis that may be applicatible on human samples is
strictly limited, we thus check the similarity of APPBP2 gene in between human and
mouse and found they are 96% identical. To know the expression pattern of
APPBP2/PAT1a and if it is expressed in mouse brain, Northern analysis was
performed on blots loaded with mRNA samples from multiple mouse tisseus. The
APPBP2/PAT1a transcripts were detected with most pronounced levels in heart,
brain, spleen, kidney in mice (Fig.3.2.2).
Fig.3.2.2: Northern analysis of APPBP2/PAT1a transcripts in multiple adult
mouse tissues and different stages of mouse embryonic brains. The transcripts
detected at 6.5 kb perfectly matched the predicted size of the APPBP2/PAT1a cDNA
(6,48kb) as mentioned before. Notable,the longest PAT1a transcript in mouse spleen
had a size of 6.2 kb instead of 6.5 kb and in testis, two transcripts with a length of 6.5
kb and 6.2 kb were found. Right panel revealed levels of PAT1a transcripts during
early development. Interestingly, in the course of development some variations in the
expression level were observed. The bands at 6.5kb shows high levels of transcripts
at embryonic day 7 (E7, 7 days after gestation), decreased at E11 and significantly at
E15,but elevated at later stage.At E11 and E17,the signals were similar, suggesting
that this full length APPBP2/PAT1a mRNA level is regulated during embryonic
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development. Remarkably, the expression level of the 4.3 kb transcript were equal
during development. (H.: heart; B.: Brain; Spl.: spleen; Liv.: liver; L.: Lung; S.M.:
skeleton muscle; K.: kidney; P.: pancreas; E#: embryonic stages). Rehybridization
with a random 32P-labelled cRNA probe derived from ß-actin cDNA confirmed that
comparable amounts of various mRNA were loaded (lower panels).
3.3. In situ Analysis of APPBP2/PAT1a transcripts in adult    
mouse brains
3.3.1. APPBP2/PAT1a is predominantly expressed in neurons in mouse brain
Northern analysis had shown the presence of APPBP2/PAT1a transcripts in the
brain, the next would be to verify in detail the cellular expression of APPBP2/PAT1a
transcripts in mouse brain, in situ hybridization was performed with randomly DIG-
labeled cRNA probes (alkaline hydrolyzed to 200-500bp), and the result showed that
APPBP2/PAT1a transcripts are widely distributed in brain, predominantly expressed
in neurons. The strongest signal was detected in cell-dense areas such as cortex, the
Purkinje cell layer in the cerebellum, the dentate gyrus and CA1-3 region in the
hippocampus, whereas no significant staining of glial cells was observed(Fig.3.3.1).
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Fig. 3.3.1: in situ hybridization analysis of APPBP2/PAT1a transcripts in adult
mouse brain. (a)APPBP2/PAT1a transcripts were found widely distributed in brain
and are predominantly expressed in neurons. The strongest signal was detected in
cell-dense areas such as cortex, the Purkinje cell layer in the cerebellum and the
dentate gyrus and CA1-3 region in the hippocampus, whereas no significant staining
of glial cells was observed. No significant signal was found using the corresponding
sense probe. Bar=200um. (b.)High magnification clearly shows a cytosolic pattern,
underlining the specificity of the hybridization signals. Bar=50um.
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3.3.2.    Comparison of APPBP2/PATa expression levels in various sub-regions
among adult mouse brain
Distribution of APPBP2/PAT1 transcripts in mouse brain
Cortex ++++
Corpus Callosum -
Hippocampus CA1 ++++
CA2 +++
CA3 ++++
DG +++++
Striatum +
Amygdala +++
Thalamus +
Olfactory bulb +
Cerebellum Molecular Layer +
PC Layer +++++
Granular Layer +++
Brain stem +
Pons +
      Signal Intensities: -, none
+. low
      +++, intermediate
      ++++, high
      +++++, very high
Table 3.3.2: Comparison of signal intensities from in situ analysis. Every 3 of
whole transverse and saggital sections were observed in identical light path and
strength. Cortex, hippocampus and amygdala are affected and known strongly
correlated to the progression of AD, whereas brain stem and pons are known not
affected in the course of AD.
                                                                                                                            Results
29
3.4. Western Analysis of Subcellualr localization of  APPBP2/PAT1a in
          COS-7 cells
3.4.1. Presence of APPBP2/PAT1 in membrane fraction
Primary sequence analysis revealed that APPBP2/PAT1a exhibit no predictable
membrane spanning domain, and based on the reported interaction with APP, it was
reasonable to assume that APPBP2/PAT1a shall be present in both the cytosolic
fraction and the membrane fraction after ultracentrifugation (40,000Xg) of the
postnuclear supernatant. To test this, COS-7 cells were transiently transfected with
recombinant APPBP2/PAT1a-HA and collected for membrane preparation 24hr post-
transfection. Western analysis of the resulting samples were performed and the
result showed that APPBP2/PAT1a is partly detectable in membrane fraction as
where APP present.
       
Fig.3.4.1: Western blot the of membrane preparation of APPBP2/PAT1a.
APPBP2/PAT1a is partly detectable in membrane pool as where APP is present. (C:
cytosolic fraction, M: membrane fraction). APP fractionation was performed in parallel
to serve as a preparation control.
3.4.2. Depletion of Membrane bound APPBP2/PAT1a by Carbonate Extraction
With consideration of that, if the presence of APPBP2/PAT1a in the membrane
fraction representing the association but not anchoring characters of APPBP2/PAT1a
to the subcellular membrane compartments, the treatment of high pH carbonate
(pH=11) to the postnuclear supernatant should result the disappearance of
APPBP2/PAT1a from the membrane fraction of membrane preparation.
                                                                                                                            Results
30
Fig.3.4.2: Western blot of APPBP2/PAT1a after carbonate extraction.
APPBP2/PAT1a is an attached membrane protein. Membrane associated
APPBP2/PAT1a was deattached from membrane by carbonate treatment (ph=11),
could only be detected in the cytosolic fraction (left panel) (C: cytosolic fraction, M:
membrane fraction). APP fractionation was performed in parallel to serve as a
preparation control.
3.5. Characterization of polyclonal rabbit anti-PAT1a antibody
To extend the expression studies and for further analyzing APPBP2/PAT1a on the
protein level, we generated a peptide antibody directed against the carboxy terminus
of APPBP2/PAT1a (aa543-572). Like the probes described for Northern and in situ
Hybridization previously, this antibody likely will detect all APPBP2/PAT1a variants.
After collecting the evaluated high titer of anti-PAT1a anti-serum, the anti-PAT1a was
affinity purified according to procedures for other well-characterizd antibodies
Western analysis of the samples from cells overexpressing APPBP2/PAT1a-HA were
performed and the result showed that the purified anti-PAT1a antibody and an anti-
HA antibody recognized a major band in Western analysis at approximately ~67kDa
in extracts from HEK293, COS-7, Hela, and SH-SY5Y cells expressing recombinant
HA-tagged APPBP2/PAT1a, corresponding to the calculated MW (66.9 kDa) in full-
length. Importantly, no visible signal was detected with the anti-HA antibody in mock-
transfected cells, which indicates its specificity. When anti-PAT1a probed with the
extracts from mock transfected cells and wild-type cells in a double loaded amount, it
also detected a major band as above, likely representing the endogenous
APPBP2/PAT1a in contrast with the pre-immune serum of anti-PAT1a, it did not
reveal significant signal within the same source of extracts. Comparing the set of
samples loaded with extracts from wild-type and cells expressing recombinant
APPBP2/PAT1a, the later revealed a higher intensity of the major band. All of above
indicate that, the anti-PAT1a antibody recognize specifically APPBP2/PAT1a in
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Western analysis.
The same combination of test were done for  immunocytochemical assay as describe
above. Comparing anti-PAT1a with commercially well-characterized anti-HA
antibodies, the anti-PAT1a could reveal the same cellular staining pattern when
applied to cells over expressing recombinant APPBP2/PAT1a carrying HA-tag.
Comparing the staining between wild-type and cells over expressing recombinant
APPBP2/PAT1a revealed different levels of indirect fluorescence, but stained both
the cytosol and the same subcellular compartments. During the generation of the
anti-PAT1a antibody, methods that may test the specificity of the anti-PAT1a were
chosen and the results are shown in the following:
3.5.1. Anti-PAT1a may bind to selected sequence-specified APPBP2/PAT1a
c-terminal epitope at high affinity
In order to collect the highest titer of anti-PAT1a and test its affinity to the selected
peptide during production, BIACore Surface Plasma Resonance (SPR) was
performed in colaboration with Prof. Multhaup. BIAcore’s SPR technology is a label-
free technology for monitoring biomolecular interactions as they occur, in our case
the interaction would be in between the selected sequence-specified APPBP2/PAT1
peptide and the generated anti-PAT1 antibody. The dection principle relies on
surface plasmon resonance(SPR), an electron charge ddensity wave phenomenon
that arises at the surface of a metallic film(mostly gold) when light is reflected at the
film under specific conditions. What Biacore actually measures is the angle of
minimum reflected light intensity. When anti-PAT1 bind to the sensor surface coupled
with the selected APPBP2/PAT1 peptide, the concentration and therefore the
reflective angle at the surface chenges and an SPR response can be detected.
Plotting the response against time during the course of an interaction provides a
quantitative measure of the progress of the interaction, the recording plot is called a
sensorgram. SPR response values are expressed in resonance units(RU). One RU
represents a change of 0.0001° in the angle of the intensity minimum. For most
proteins, this is roughly equivalent to a change in concentration of about 1pg/mm2 on
the sensor surface. The exact conversion factor between RU and surface
concentration depends on propertiesof the sensor surface (in our case is a thin layer
of gold) and the nature of the molecule responsible for the concentration changes.
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(Details in Material and methods). The SPR results showed that, the anti-PAT1a
antibody binds in an affinity at least 150 pg/mm2 to the selected APPBP2/PAT1a
peptide.
Fig.3.5.1: Result of anti-PAT1a tested by BIACore Surface Plasmon Resonance
(SPR). RU: resonance units. Time scale: msec. One RU represents a change of
0.0001° in the angle of the intensity minimum. For most proteins, this is roughly
equivalent to a change in concentration of about 1 pg/mm2. Recording started when
the sample anti-PAT1a flow in passing through the sensor surface that coupled with
the APPBP2/PAT1a peptide. The difference of RU indicated aside every recording
curve represents the affinity of the antibody to the peptide in steady status. The
lowest affinity tested (green) was 150 RU, represent the anti-PAT1a may bound in
amoung of at least 150pg/ mm2 to the APPBP2/PAT1a peptide. In practical cases,
>50 pg/ mm2 is thought to interact with good affinity (Edwards, P. R. 1995; Johnsson,
B et al., 1991).
3.5.2. Western Analysis of anti-PAT1a compared with anti-HA antibody
Based on positive results from BIAcore SPR test, further test of anti-PAT1a was
carried by Western analysis. COS-7 cells were transiently transfected with
APPBP2/PAT1a-HA and the cells were harvested 24hr post-transfection.
The recognition pattern of anti-PAT1a with highly expressed APPBP2/PAT1a-HA
protein samples in comparision with the well-characterized, commercially available
anti-HA antibody (Roche) is showing in (Fig.3.5.2).
3.5.3. Immunocytochemical Analysis of anti-PAT1a compared with anti-HA
antibody
To test if anti-PAT1a may be suitable for immunocytochemical approaches,
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immunocytochemical staining in comparison with anti-HA antibody to cells collected
in parallel within the above mentioned Western analysis was performed. The result
revealed positive staining of anti-PAT1a to its target protein APPBP2/PAT1a tagged
with a HA-epitope and the same pattern in comparison with the anti-HA antibody.
Fig. 3.5.2: Anti-PAT1a recognizes APPBP2/PAT1a with high specificity in
Western analysis. The anti-PAT1a antibody and an anti-HA antibody recognized a
major band at ∼67kDa in extracts of cells expressing recombinant HA-tagged
APPBP2/PAT1a (lanes indicated with “+”), which matched to the calculated MW
(66.9 kDa). No significant signal was detected with the anti-HA antibody in mock
transfected cells (lanes indicated with “–”). The anti-PAT1a antibody recognized the
wild type sample loaded in triple amount a major band at ∼67 kDa, likely representing
the endogenous PAT1a. No bands were detected in lanes probed with pre-
immunoserum (Pre.) representing high specificity of anti-PAT1a antibody.
Fig.3.5.3: Anti-PATa shows the same staining pattern as anti-HA antibody.
Double staining with the anti-PAT1a (green) and anti-HA (red) antibodis to verify the
specificity of anti-PAT1a to APPBP2/PAT1a revealed an identical staining pattern.
Note, with the anti-PAT1a antibody staining an adjacent cell with weaker
immunoreactivity of anti-PAT1a was detected which might represent the endogenous
APPBP2/PAT1a level and reveal the anti-HA has no cross-reactivity to any
endogenous protein in this cell type.
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3.5.4. Immunopercipetation Analysis of anti-PAT1a antibody
To test if the anti-PAT1a antibody could be utilized for immunoprecipitation (IP)
approaches, additional characterization was designed. Our Characterization for
immunoprecipitation approach had a convincing result as well. Protein lysates from
cells overexpressing the recombinant HA-tagged APPBP1/PAT1a were subjected to
immunoprecipitation procedures with either the pre-immunoserum of anti-PAT1a and
anti-PAT1a. The resulted immunoprecipitates were analysized and revealed no
detectable band from the pre-immunoserum and a clear band from the anti-PAT1a at
the expected size in contrast with a lane loaded with 20% input, which indicated that
anti-PAT1a could immunoprecipitate its target protein, APPBP2/PAT1a.
Fig. 3.5.4: The antiPAT1a antibody immunoprecipitates specifically. Anti-PAT1a
immunoprecipitates APPBP2/PAT1a-HA protein whereas the immunoprecipitation
performed with pre-immune serum(Pre) shows no positive signal in contrast to the
lane loaded with 20% input sample. The presence of IgG bends revealed that in our
cases there are cross-spices activity occurred between the capturing antibodies for
IP and the secondary detection antibodies for IB: immunoblotting.
3.6. Distribution of APPBP2/PAT1a in various cell lines and
      mouse tissues
Based on the results from characterization of anti-PAT1a, we could conclude that this
rabbit anti-PAT1a is specific and suitable to be utilized for approaches on
endogenous expression of APPBP2/PAT1a. Prior to this with combined evaluation of
BIAcore SPR result, the anti-PAT1a was affinity purified with the same peptide for the
immunorization in order to enhanced the purity of this antibody. In previous
characterization of anti-PAT1a antibody that showed it recognizes a major band at
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∼67 kDa, likely representing the endogenous PAT1a, however, in this test the criteria
of sample amount loaded was minimal, only to bring visible signals. With reference
back to the Northern results, the APPBP2/PAT1a transcripts levels varied highly
among tested tissues, it was reasonable to consider an increasing amount of loading
samples in order to avoid wrong evaluation of endogenous expressing
APPBP2/PAT1a from different cell lines and mouse tissues. After the protein
concentration was determined, 80ug/lane of samples were loaded to proceed the
analysis of endogenous expression of APPBP2/PAT1a.
3.6.1. Expression pattern of APPBP2/PAT1a differs in different cell lines.
Various cell lines available in our group were used. Lysates from wild type COS-7,
HEK293, SH-SY5Y, Hela cells, primary mouse cortical neurons (DIV7) were collected
with normal morphological condition. Lysates from different cell lines overexpressing
APPBP2/PAT1a-HA except primary neurons were also collected for analysis, since
the size of HA epitope is about 3 kDa, the gel system used for this analysis could not
differentiate the size difference in between APPBP2/PAT1a and APPBP2/PAT1a-HA,
so that the later samples may served to indicate the correct position of bends
represent APPBP2/PAT1a.
Fig.3.6.1: Western Analysis of endogenous APPBP2/PAT1a and recombinant
APPBP2/PAT1a-HA in different cell lines. The anti-HA and anti-PAT1 antibodies
recognized in extracts of cells expressing recombinant HA-tagged APPBP2/PAT1a
(+) or endogenous APPBP2/PAT1a a major ∼67kDa band (arrowhead) and several
signals with lower MW, including 47kDa and 35kDa, possibly representing carboxy
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terminal cleavage products of APPBP2/PAT1a or putative APPBP2/PAT1a splice
variants. No signal was found in non transfected cells (-). Note, that the pattern of low
molecular bands varies in the different cell types.
3.6.2.  Ubiquitous expression of APPBP2/PAT1a in multiple mouse
             tissues is in high complexity
In this step, extracts of multiple mouse tissues were subjected for Western analysis
using the previousily characterized and affinity purified anti-PAT1a antibody. The
result showed that, besides the major band at ∼67kDa, additional signals at 72kDa
and also at lower molecular weight were detected. The ∼67kDa band was found in all
tissues, whereas the lower molecular weight forms varied in size between the
different tissues and the ∼72 kDa band was found only in some tissues. However,
based on our results with recombinant APPBP2/PAT1a-HA, we assume that the
∼67kDa form represents full length APPBP2/PAT1a, whereas the low molecular
weight forms are either cleavage products or due to alternative splicing. The ∼72 kDa
bands possibly resulted from posttranslational modifications of the ∼67kDa band. The
expression pattern of the ∼67kDa APPBP2/PAT1a form resembles the result of the
Northern analysis of APPBP2/PAT1a.
Fig.3.6.2: Western Analysis of PAT1a/APPBP2 among adult mouse tissues.
Besides the major band at ∼67kDa, additional signals at ∼72kDa and also at lower
molecular weight were detected. (L: lung; B: brain; S: spleen; H: heart; S.M.: skeleton
muscle; Liv: liver; K: kidney; Pla: placenta; 1N: primary neurons). The ∼67kDa band
was found in all tissues, whereas the lower molecular weight forms varied in size
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between the different tissues. However, based on our results with recombinant
APPBP2/PAT1a-HA (right most lane), we assume that the ∼67kDa form represents
full length APPBP2/PAT1aPAT1a, and the low molecular weight forms are either due
to posttranslational cleavage or alternative splicing. In contrast with the detection of
anti-HA to APPBP2/PAT1-HA, the pattern of low molecular weight bands varied in
different cell lines, suggesting that tissue specific or cell type specific cleavages or
modifications might occur. Consistent with this assumption, the expression pattern of
the ∼67kDa APPBP2/PAT1a form resembled the result of the Northern analysis:
pronounced levels of PAT1a were detected in brain, placenta, and kidney, whereas
only low expression was found in liver and skeletal muscle.
3.7. The distribution of PAT1a overlaps with the expression
pattern of APP family proteins
3.7.1. APLP1 is expressed in neurons in mouse brain (reconfirmed)
While looking back for references that described the neuronal expression of APLP1,
we found contradictary datas were reported by (Lorent et al, 1995) and (Heber et al
2000; and Thinakaran et al, 1995), Lorent and co-workers reported that APLP1 is
expressed in both nourons and glial cells whareas Heber and co-workes, and
Thinakaran reported that APLP1 is expressed strickly in nourons. Thus, it needed to
be re-investigated, clarifing the statement in protein level. Considering the available
materials, we used the commercially well-characterized anti-APLP1 antibody (CT-
11), that was raised against the human APLP1 carboxyl terminal residues (640-
650aa), which may recognize mouse APLP1 as well. Immunohistochemical and
immunohisto fluorescence staining on mouse brain sections were performed, and to
ensure any presence of nonspecific reactivity with this antibody, brain sections from
APLP1-/- mice were used as control (Fig. 3.7.1).
3.7.2. Overlapped expression of PAT1a/APPBP2 to APP family members in
mouse brain is highly susceptible to neurodegeneration in AD
To extend the study of APPBP2/PAT1a expression pattern in protein level, and to
investigate if it is distributed in brain regions that highly affected by AD, this is rather
an important issue to propose any link to AD pathologenesis. Immunohistochemical
analysis of mouse brain sections with anti-PAT1a antibody was performed.
Immunohistochemical analysis of mouse brain sections using anti-PAT1a antibody
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revealed a widespread and predominantly neuronal expression. Importantly, there is
no obvious significant signal could be detected by using the pre-immunoserum of
anti-PAT1a antibody. Interestingly, PAT1a was present both in the soma and distal
neurites of pyramidal neurons, whereas in Purkinje cells only the cell body and
proximal neurites were stained, suggesting a differential cell type specific expression
of PAT1a. Besides this, a weak staining of glial cells was observed, as indicated by
colocalization with GFAP. In contrast with in situ analysis which has no signal shown
on glial cells, we think the possible reasons would be that, the APPBP2/PAT1a
mRNA transcripts in glial cells is lower than our detectable range but is sufficient to
generate low but detectable APPBP2/PAT1a protein.
The result revealed a widespread predominant neuronal expression with high level in
the cortex and hippocampus that are affected in AD, which shows agreement to our
in situ data (Fig.3.7.2).
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Fig.3.7.1: Immunohistochemical Analysis of APLP1 expression pattern in
mouse brain. (a)APLP1 was found widely distributed in mouse brain and the
expression is strictly in neurons. The signals were detected and obvious in cell-dense
areas such as cortex, the Purkinje cell layer (PC) in the cerebellum and the dentate
gyrus and CA1-3 region in the hippocampus, whereas no significant signal was
observed on brain sections from APLP-/- mouse. Bar=200um. (b)High magnification
clearly shows a cytosolic staining with extension to the apical neuritic region.
Bar=50um. (c) Double staining of APLP1 with GFAP revealed no overlapping
expression, agreed with the in situ experiment that APLP1 is expressed strictly in
neuronal cells. Bar=50um.
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Fig.3.7.2: APPBP2/PAT1a immunohistochemical stain of mouse brain sections.
(a)APPBP2/PAT1a was found widely distributed in mouse brain and the expression
is predominantly in neurons. The signals were detected in cell-dense areas such as
cortex, the Purkinje cell layer (PC) in the cerebellum and the dentate gyrus and CA1-
3 region in the hippocampus, whereas no significant signal was observed on brain
sections that probed with pre-immune serum. Bar=200um. (b)High magnification
clearly shows a cytosolic staining with extension to the apical neuritic region.
Bar=50um. Notably, PAT1a was present in the soma and apical dendrites of
pyramidal neurons, whereas in Purkinje cells only the cell body and proximal neurites
were stained, suggesting a differential cell type specific expression of
APPBP2/PAT1a. (c) Double staining of APPBP2/PAT1a with GFAP revealed slightly
overlapping expression, suggesting that APPBP2/PAT1a may be expressed in lower
level in glial cells. Bar=50um.
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3.8. Colocalization of recombinant APPBP2/PAT1a and APP
     family proteins in subcellualr membrane compartment in
     primary mouse E14 cortical neurons (DIV 7)
3.8.1. APPBP2/PAT1a is transported to both dendrites and axons
We next investigated the cellular localization of APPBP2/PAT1a-HA in primary
neurons. For this purpose, we transfected primary neurons differentiated for 7 days in
vitro (DIV7), with cDNA encoding HA-tagged APPBP2/PAT1a.
  
Fig.3.8.1: The subcellular distribution of APPBP2/PAT1a. Besides a diffuse
cytosolic staining, we observed a punctate, vesicular APPBP2/PAT1a(Red)
immunoreactivity, suggesting that APPBP2/PAT1a is partly associated with
intracellular vesicles. We also observed strong APPBP2/PAT1a immunoreactivity in
the somatodendritic compartment and in MAP2-negative (green) neurites suggesting
that APPBP2/PAT1a is localized to both dendrites and axons. However, we found no
accumulation of PAT1a in a specific subcellular compartment, such as the nucleus or
the cis/medial Golgi apparatus in neurons. Bar=50um.
3.8.2. Co-localization of APPBP2/PAT1a with APP family proteins in neurons
Concerning whether APPBP2/PAT1a co-localizes with APP, APLP1 or APLP2 in
subcellular membrane compartments, mouse primary neurons were transfected with
APPBP2/PAT1a-HA and myc-tagged APP, APLP1, or APLP2. The results reveal,
PAT1a is associated with APP/APLPs containing vesicles in the early and late
secretory pathway suggesting that APPBP2/PAT1a may be implicated in different
steps of the subcellular transport of APP, APLP1 and APLP2 from the ER/Golgi to
the cell surface. Since antibodies available from different species for  indirect
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immunoflorescence analysis were limited for APLP1 and APLP2, both have only
antibodies derived from rabbits, and our anti-PAT1a was derived from the same
species as well, so that this approach could not be done in endogenous levels,  we
therefore decided to double transfect HA-tagged APPBP2/PAT1a with each myc-
tagged APP family members. Analysis regarding the co-localization was done with 20
z-scan sections in 2um depth on every single neuron and the deconvolution
enchancement was performed with the highest ranked program. Besides, we focused
the localization on the fine structures covering neurites instead of soma region to
avoid highly saturated false positive co-distribution signals. As shown in result 3.8.,
APPBP2/PAT1a associates with vesicular membranes or organelles co-localized with
each APP family members in the distal neurites. Remarkably, most of the APLP2
positive vesicular structures co-localized with APPBP2/PAT1a, whereas the APP or
APLP1 co-localized only partly, which also agreed with the GST pull-down data from
our group that observed the strongest binding for APPBP2/PAT1a and APLP2,
suggesting that APPBP2/PAT1a may interact preferentially with APLP2 in vivo.
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Fig.3.8.2: Overall co-expression of APPBP2/PAT1a and APP family proteins in
neurons. Mixed cortical neurons were transfected with cDNAs encoding HA-tagged
PAT1a, and myc-tagged APP, APLP1 or APLP2. Cells were stained with the anti-HA
(red) and anti-myc (green) antibodies. Immunocytoflurocence analysis revealed a co-
staining (yellow) of APPBP2/PAT1a with APP, APLP1, or APLP2 not only in the cell
soma, but also in vesicular structures of distal neurites. Remarkably, most of the
APLP2 positive vesicular structures co-localized with APPBP2/PAT1a, whereas the
overlap of APP or APLP1 staining with that of APPBP2/PAT1a staining was lower.
Bar=50um.
3.8.3. APPBP2/PAT1a is co-localized with APP family proteins in subcellular
membrane compartments
To show clearly the co-localization of APPBP2/PAT1a in subcellular compartments,
enlarged views of selected regions focusing on the distal neurites form the previous
overviews (Fig.3.8.2) of whole neurons are showing below:
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Fig.3.8.3: Detail Co-localization of APPBP2/PAT1a in vesicular structures.
Higher magnification of the area marked in the merged images (Fig.3.8.2) by a
square. In these enlarged views, subcellular compartments may be seen clearly to
reveal the co-distribution (yellow) of APPBP2/PAT1a (red) and APP family proteins
(green). However, The specific subcellular compartments could not be differentiated
in this study because lack of markers. These structures might present transport
vesicles, endosomes or lysosomes. Bar=50um.
3.9. In vivo interaction of  APPBP2/PAT1a and APP family
     proteins in mouse CNS
PAT1 was shown to interact directly with APP in vitro, however further evidence to
prove the existence of in vivo interaction was considered necessary for AD
researches. Previously, We have shown that APPBP2/PAT1a presents in the
membrane fraction of the postnuclear supernatant, and this presence was depleted
when the supernatant was subjected to high pH carbonate treatment prior to the
membrane preparation.  Above lays barely, APPBP2/PAT1a, without any predictable
membrane spanning domain, is partly associated with membrane compartments
where the APP family proteins also present. While the other works in our group were
reconfirming the in vitro binding by Western analysis and in parallel checking if the
other two mammalian homologous of APP might interact with APPBP2/PAT1a in vitro
as well since they are from an highly conserved gene family,  this study moved on
directly to analyse the in vivo interactions between APPBP2/PAT1a and APP family
members in mouse central nerves system. Co-immunoprecipitation approaches were
performed to answer these questions. The anti-PAT1a antibodies has been
characterized well that can immunoprecipitate it target protein APPBP2/PAT1a, we
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utilized it as the capturing antibody to precipitate the immunocomplexes that
associate with APPBP2/PAT1a in adult mouse brain.  Pre-immune serum of anti-
PAT1a was used to serve as a control experiment, which may indicate if the
presence of any APP family proteins was resulted by non-specific co-precipitation.
Comparative quantification of the interacting affinity among different family members
was not performed because of that, for APLPs, the capturing antibodies and
detection antibodies are from the same species, whereas in the experiment of APP
were different. Using same species of capturing and detection antibodies in co-
immunoprecipitation would reveal uniformed strong bands of immunoglobulins, in our
case, would overlap with bands of each APP family members. We thus have to
couple the capturing antibodies for co-immunoprecipitating APLPs which most likely
would cause an non-equal  amount of  capturing antibodies used while performing
the experiments and therefore would result an unreliable quantification.
The co-immunoprecipitation experiments clearly revealed that all three members
exist in a common complex with APPBP2/PAT1a in vivo in the mouse central nerves
system, which agreed with the data from our group that shows, in vitro synthesized
APPBP2/PAT1a could be pulled down by in vitro translated GST-fused intracellular
domains of APP, APLP1 and APLP2 (Tomas Grübl unpublished data).
3.9.1. APP can be co-immunoprecipitated with APPBP2/PAT1a from in vivo
sample source.
Started with APP, mouse brains were collected and homogenized as described in
Meterials and methods. Co-immunoprecipitation was performed with anti-PAT1a as
the capturing antibody, Pre-immune serum and sepharose beads only(-) severed as
controls in parallel. Western analysis (IB) of the immunoprecipitates was done with
monoclony mouse anti-APP (22C11) since there was no cross reactivity of mouse
anti-IgG to rabbit IgG (anti-PAT1a) observed in our system. We performed 2
methods, one set, the IP capturing antibodies were uncoupled to the protein A
Sepharose beads, the other set, the capturing antibodies were covalently coupled to
saphorose beads prior to the immunoprecipitation reaction.
                                                                                                                            Results
46
Fig.3.9.1: Presence of APP in the immunocomplexes of anti-PAT1a. APP was
co-immunoprecipitated with the anti-PAT1a antibody, but not in the absence of IP
antibody (-) or with the adjacent pre-immuno serum. Comparison between two sets of
results revealed that the technical difference would cause non quantifiable binding
ratio between APPBP2/PAT1a and APP.  In the case of uncoupled IP antibodies (left
panel), it revealed about 0.3% of APP binds to APPBP2/PAT1a (left panel) whereas
when the antibodies were coupled to the Sepharose beads (right panel), it revealed
only 0.1% of APP binds to APPBP2/PAT1 in mouse brain, this most likely was
caused by the loss of antibody while coupling.
3.9.2. APLPs can be co-immunoprecipitated with APPBP2/PAT1a from in vivo
sample source.
After fonud the evidence of in vivo interation between APPBP2/PAT1a and APP, the
next is to test if APPBP2/PAT1a also interacts with APLPs, co-immunoprecipitation
was also performed with the capturing anti-PAT1a antibody and pre-immuno serum
coupled to the Sepharose beeds. Mouse brains were collected and homogenized in
lysis buffer as described in Meterials and methods, then proceed to the
immunoprecipitation reaction. Western analysis of the immunoprecipitates showed
that bothe APLP1, APLP2 present in anti-PAT1a immuno complexes.
Fig.3.9.2: Presence of APLPs in the immunocomplexes of anti-PAT1a. APLPs
were co-immunoprecipitated with the anti-PAT1a antibody, but not in the absence of
IP antibody (-) or with the adjacent pre-immuno serum. Approximately, 0.2% of
APLP1 may bind to APPBP2/PAT1a (left panel), 0.1% of APLP1 may bind to
APPBP2/PAT1a (right panel) in mouse brain. Note, these experiments were
performed with the coupled capturing antibodies to the Sepharose beads.
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3.10. Processing of APP family proteins may be affected by
      regulation of APPBP2/ PAT1a levels
To test the consequences of the interaction between APPBP2/PAT1a and APP
family proteins, the influence of APPBP2/PAT1a on APP/APLPs processing was
examined. If APPBP2/PAT1a has a function in the control of the subcellular transport
of APP/APLPs, it should affect their proteolytic cleavages. We used neuroblastoma
cells (SH-SY5Y) stably expressing APP, APLP1 or APLP2 fused to a tandemly
repeated z domain (2z) of proteinn A, which facilitates the detection of the
APP/APLPs C-terminal fragments (CTFs) (Eggert et al., 2004a; Weidemann et al.,
2002c). These cells expressing APP-, APLP1- or APLP2-2Z were transiently
transfected with cDNAs encoding APPBP2/PAT1a-HA, an empty vector (mock) or
small interfering APPBP2/PAT1a (siPAT1a), which causes a reduction of PAT1a
protein level of about 50%-70% (Fig.3.10.1). Cells co-expressing APPBP2/PAT1a-
HA produce elevated levels of sAPP, sAPLP1 and sAPLP2, as well as increased
amounts of c-terminal fragments, whereas the reduction of the APPBP2/PAT1a
levels led to decreased secretion of sAPP/APLPs and less CTF production
(Fig.3.10.2). All detected CTFs were reduced to a similar extent, suggesting that
PAT1a facilitates the transport of APP/APLPs towards the late secretory pathway,
where α- and β-cleavage take place.
3.10.1.  Alteration of APPBP2/ PAT1a by small interfering application
To move further for functional study of APPBP2/PAT1a, establish a system that may
allow us to regulate the APPBP2/PAT1a levels was necessary. We applied both
small interfering RNA (siRNA) and antisense techniques to modulate the
endogenous APPBP2/PAT1a level. We found the siRNA technique could affect more
than the antisense application in the human neuroblastoma cell line (SH-SY5Y), we
thus utilized it to perform our analysis on the processing of APP family proteins.
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Fig. 30.10.1: Western analysis of down regulation of APPBP2/PAT1a. siPAT1a
may down regulate both recombinant and endogenous APPBP2/PAT1a (upper
panel). The siPAT1a co-transfected with APPBP2/PAT1a-HA caused a suppression
of recombinant APPBP2/PAT1a-HA about 70% and caused a suppression of the
endogenous APPBP2/PAT1a level about 50% in SH-SY5Y cells, whereas the β-actin
level remained unchanged (lower panel).
3.10.2.  APPBP2/PAT1a affects APP/APLPs processing
The influence of APPBP2/PAT1a on the generation of CTFs and secreted forms of
APP/APLPs (sAPP, sAPLP1 and sAPLP2) was analyzed in SH-SY5Y cells that were
stably expressing APP-, APLP1- or APLP2-2z constracts and transiently transfect
with APPBP2/PAT1-HA (PAT1a-HA) cDNA, empty vectors (mock) or small interfering
APPBP2/PAT1a (siPAT1a) vector. After 48h, medium containing sAPP, sAPLP1, or
sAPLP2, and the cell extracts containing full length (fl) and carboxyl terminal
fragments (CTFs) of APP, APLP1 and APLP2 were subjected to Western analyses.
Cells co-expressing APPBP2/PAT1a-HA produce elevated levels of sAPP, sAPLP1
and sAPLP2, as well as increased amounts of C-terminal fragments, whereas the
reduction of the APPBP2/PAT1a levels led to decreased secretion of sAPP/APLPs
and less CTF production (Fig.3.10.2).
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Fig.3.10.2: Western Analysis of APP family proteins after up/down regulation of
APPBP2/PAT1a. The influence of APPBP2/PAT1a on the generation of CTFs and
secreted forms of APP/APLPs (sAPP, sAPLP1 and sAPLP2) was analyzed.
Regulation of APPBP2/PAT1a were designed to transiently transfect APPBP2/PAT1a
cDNA, empty vectors (mock) or small interferring APPBP2/PAT1a cDNA (siPAT1a).
After 48h, medium containing sAPP, sAPLP1, or sAPLP2, and the cell extracts
containing full length (fl) and carboxyl terminal fragments (CTFs) of APP, APLP1 and
APLP2 were analyzed. The full length of each proteins were normalized to the same
amount (the upper most panel), to allow determination of the change of the
generated CTFs and s-forms of each family proteins. Interestingly, we observed that
cells co-expressing PAT1a produce elevated levels of sAPP, sAPLP1 and sAPLP2,
as well as increased amounts of C-terminal fragments, whereas the reduction of the
APPBP2/PAT1a levels led to decreased secretion of sAPP/APLPs and less CTF
production. Notably, all detected CTFs were reduced to a similar extent, suggesting
that the transport of APP/APLPs towards the late secretory pathway, where α- and β-
cleavage take place, might be facilitated by APPBP2/PAT1a.
3.10.3.  Quantification of the effects on the processing of APP family proteins
Quantification based on densitometric measurements were done by measuring the
intensity of each bend resulted from above Western analysis. The results revealed
significant influences.
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Fig.3.10.3: The amounts of sAPP/APLPs and CTFs generated in APPBP2/PAT1a
overexpressing cells (black bars), mock transfected cells and siPAT1a treated cells
(gray bars) were quantified. The relative amounts of CTFs and secreted fragments in
comparison to mock transfected cells (set to 1) are shown. APP/APLPs fl protein
levels varied in the range of less than +/- 5%. Error bars show standard deviations of
the mean (n=3).
3.10.4.  Quantification of the effects on Aβ production
To determine the effects on Aβ secretion, sandwich ELISA were performed with the
medium collected from the cells that were examined for the influence on the
processing by regulating the APPBP2/PAT1a levels. As mentioned before, the
medium were collected 48hr post-transfection (affecting period 48hr), alternatively,
the media were changed 36 hr post-transfection, then collected for analysis at the
48th hr post-transfection (affecting period 36-48 hr) for the ELSIA. Since we
observed the peak of siPAT1a influence occurred during this period, thus was
reasonable to think the maximal influence by regulating APPBP2/PAT1a should
present in the same period as well. Our results proved the consideration, and reveal
that regulation of APPBP2/PAT1a level favors the generation of Aβ42 than Aβ40 and
the effects on Aβ42 is stranger than Aβ40.
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Fig.3.10.4: Quantification of the influence on Aβ production., Medium from the
experiments of APP processing containing Aβ were collected as mentioned. The
amounts of Aβ in APPBP2 overexpressing cells (black bars), mock transfected cells
and siPAT1a treated cells (gray bars) were quantified. The relative amounts of Aβ  in
comparison to mock transfected cells (set to 1) are shown. The APP/APLPs full-
length (fl) protein levels varied in the range of less than +/- 5% was checked in
(Fig.3.10.3). Error bars show standard deviations of the mean (n=3).
.
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4. Discussion
4.1. Why is PAT1 a rare variant of its representative gene in
human brain?
Starting cloning of PAT1, we found all of our resulted PCR products containing
constantly several mutations in alignment to PAT1 sequence. Database analysis
revealed that the sequence of PAT1 results from an infrequent polymorphism of the
APPBP2 gene.  We cannot exclude that this could be resulted from different sources
of cDNA that were used as templates while performing amplification. PAT1 was
amplified from Hela cell cDNA (Zheng et al., 1998), and our APPBP2/PAT1a was
amplified from human brain cDNA library. Interestingly, an androgen receptor
associated protein (Ara67) was amplified from human testis cDNA library and
described in recent (Zhang et al. 2004), which is 99,6% homologous to PAT1, this
likely represents an additional variant of APPBP2/PAT1a, suggesting a high
polymorphism in this gene.
Considering for AD research, we recommend, the accurate genetic information
obtained from human brain shall be a more appropriate source. We also analyzed 53
ESTs covering the region of PAT1 cDNA containing the nucleotide exchanges.
Unexpectedly, all tested EST sequences were identical with the sequence of
APPBP2, but none was equal to PAT1, suggesting that the PAT1 sequence likely
represents a rare variant of APPBP2. From some personal conversations with other
groups that ever interested in working on PAT1, we found they all failed to reconfirm
the interaction by western analysis with the recombinant PAT1 provided by (Zheng et
al., 1998), which probably would explain why no occurrence of any following study
could be found to date, this might due to the 6 amino acids exchange in between
PAT1 and APPBP2/PAT1a. Further investigations shall  be necessary to determine
the precise frequency and to test whether these exchanges will result a consequence
on the binding properties to APP/APLPs and if these polymorphisms might affect the
risk for AD. In this context it will be further interesting to test the specific
characteristics of the putative APPBP2/PAT1a splice variants.
                                                                                                                    Disscussion
53
4.2. APPBP2/PAT1a has 3 transcripts and is highly expressed in
the areas where severely affected in the course of AD.
A neuronal function in subcellular transport of APP for PAT1 was proposed (Zheng et
al. 1998). However, no study addressing its expression in brain has been performed.
Therefore, analysis the neuronal expression of APPBP2/PAT1 is rather an important
issue to propose any link to AD pathology.
Northern analysis In this study shows that APPBP2/PAT1a gene may encode three
transcripts with the length of 6.5 kb, 4.3kb and 2.3kb. In contrast with all published
Northern analysis of PAT1 among different cancer cell lines (Maarit, Cancer
Research 2000); or its synonyms KIAA0228 (Nagase et al. 1996) including different
human and mouse tissue and nonepithelial cells; or its variant Ara67 (Zhang et al.
2004) including human tissues and multiple cell lines. Our result reveal the same
pattern and clear bands, which provide further specific data of APPBP2/PAT1a
transcripts in natural sources from various human and mouse tissues. Worth to
mention, our result shows that the APPBP2/PAT1a transcripts may be detected with
most pronounced levels in brain, placenta, and kidney in human which differs from
the study done by (Zhang et al. 2004). In their study, they concluded, “strong
expression of Ara67/PAT1 transcripts were seen in skeletal muscle, placenta, and,
heart “. Reference back to the figure of their Northern data, we found, the author did
not normalize the expression levels to the control ß-actin transcripts which exhibited
in diverse levels while our detection of ß-actin transcripts exhibited comparable
amounts of mRNA that were loaded.
APP was shown to be expressed in both neurons and glial cells among all regions in
the brain, when affected by AD, was observed to be up regulated in the frontal cortex
and the hippocampus (Cras et al., 1991). The regional, subcellular distribution of
APLP1 and APLP2 was shown to overlap with each other and with APP (McNamara
et al., 1998), but cellular expression of APLP1 was shown strickly in the neurons
(Thinakaran G, 1995; reconfirmed in this study). In AD brain, both were examined to
accumulate in the large dystrophic neurites in a subset of senile plaques (Bayer et
al., 1997; Crain et al., 1996; McNamara et al., 1998). Our in situ hybridization shows
that, all 3 transcripts of of APPBP2/PAT1a detected in the Northern analysis are
distributed in mouse brain predominantly in neurons and widely overlaps with the
expression of APP/APLPs and is highly expressed in the areas that are severely
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affected in the course of AD (Table 3.3.2).
4.3.Do we have a specific and reliable polycoloned anti-
APPBP2/PAT1a antibody?
As shown in the Results 3.5., the BIACore SPR result revealed, the generated anti-
PAT1a antibody has relatively high affinity to the selected peptide from standard
technical views, it surely can recognize the epitope selected from APPBP2/PAT1a,
and most likely will recognize APPBP2/PAT1a.  Western analysis of the recognition of
anti-PAT1 to its target protein revealed a predominant band at the expected size, and
the immunoprecipitation test showed that the anti-PAT1a may bind to APPBP2/PAT1a
under non-denatured condition. Immunocytofluorescence analysis revealed the anti-
PAT1a may exhibit the same staining pattern as anti-HA antibody.
In brief, we did BIAcore SPR analysis, test for immunoprecipitation, Western and
immunocytochemical analysis, plus the affinity purification to ensure the anti-PAT1a
is in a high quality of specificity. Although there are other techniques that may be
apply to characterize an antibody, such as ELISA and pre-absorption, that represent
similar principles as BIAcore and Affinity purification. With all the characterization
works done for anti-PAT1a, we believe, this anti-PAT1a antibody reveals high
specificity to not only its antigen, the selected peptide of APPBP2/PATa, but also to
the target protein, APPBP2/PAT1a, and its other full-length variants or cleavage
products containing the selected epitope.
4.4. Expression of APPBP2/PAT1a proteins in vivo is in high
complexcity
The anti-PAT1a and anti-HA antibodies both recognized a major band at
approximately 67kDa in extracts from different cells expressing recombinant HA-
tagged APPBP2/PAT1a, corresponding to the calculated MW (66.9 kDa). In addition,
we also observed lower molecular weight minor bands with both antibodies, which
we believe, may be carboxyl terminal cleavage products or represent spliced variants
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of APPBP2/PAT1a since at least 3 transcripts were consistently found in a detectable
range among all Northern analysis of the same gene transcripts. As the protein
pattern of low molecular weight bands varied in different cell lines, indicated that
APPBP2/PAT1a is possibly differentially spliced or processed in different cell types.
With reference to all different Northern data showing in the other references and in
this study, it clearly revealed that APPBP2/PAT1a transcripts contain three splicing
variants, so that is reasonable to believe, likely may result at least three protein
products if all in nature are being encoded for protein production. Mature proteins
often accomplished with posttranslational modification, and hence may be subjected
under goes processing for physiological functioning. Concerning all above
possibilities thus made difficulties to predict band pattern that can be detected by
Western analysis when the sample sources are from highly complicated organisms.
In additional, protein products lack of the selected epitope for antibody generation
would result no appearance to the analysis, which will reveal less unique band
pattern comparing with Northern analysis. However, we still cannot exclude any
specific cross reactivity that may occur during probing the characterized specific anti-
body to denatured protein samples for western analysis. If this could come to an
argument after carefully characterized the specificity of an antibody, then would
argue a huge pool of existing antibodies, since it is also possible, a specific cross
reactivity occurs on expected size of the target protein. Our over expression and
down regulation of APPBP2/Protein have proved the anti-PAT1a is surely specific to
APPBP2/PAT1a since the detection intensity varies when regulating APPBP2/PAT1
protein levels.  We thus believe that the in vivo APPBP2/PAT1a protein expression is
rather complicated.
4.5. APP family members can be detected in APPBP2/PAT1a
immunocomplexes and observed existing in the same
subcellular membrane compartments
Pimplikar and co-works only provided the in vitro interaction, which brought
reasonable doubts if the evidence was too weak and might be in a false positive
range when applying in vitro binding assay. Concerning the matter of fact, evidence
of in vivo interaction is thus valuable to address better links of APPBP2/PAT1a to
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APP pathological role of AD.
This study clearly shows that the subcellular co-localization of APPBP2/PAT1a and
APP family members in primary mouse neurons were observed in membrane
compartments, and all three members exist in a common complex with
APPBP2/PAT1a in vivo in the mouse central nerves system by co-
immunoprecipitation experiments, which agreed with the data from our group that
shows, in vitro synthesized APPBP2/PAT1a could be pulled down by in vitro
translated GST-fused intracellular domains of APP, APLP1 and APLP2 (Tomas Grübl
unpublished data). In conclusion, our data suggest that APPBP2/PAT1a is associated
with membranes containing APP/APLPs, indicating that APPBP2/PAT1a may be
implicated in different steps of the subcellular transport of APP, APLP1 and APLP2
from the ER/Golgi to the cell surface and/or futher to endosomes.
4.6. The processing of APP family members and production of
Abeta are influenced by regulating APPBP2/PAT1a levels
This study shows that cells co-expressing APPBP2/PAT1a produce elevated levels
of sAPP, sAPLP1 and sAPLP2, as well as increased amounts of C-terminal
fragments, whereas the reduction of the APPBP2/PAT1a levels led to decreased
secretion of sAPP/APLPs and less CTFs production. Since α- and β- cleaved CTFs
were reduced to a similar extent. Combine with the reported properties of PAT1, a
KLC-like protein interacting with the BaSS of APP suggesting that, APPBP2/PAT1a
facilitates the transport of APP/APLPs towards the late secretory pathway, where α-
and β-cleavages take place.
Neurons are thought to be the main source of Aβ in brain (Turner et al., 2003) and as
this study reveals that APPBP2/PAT1a affects APP/APLP processing in neuronal
cells, it is feasible that APPBP2/PAT1a has a regulatory function in Abeta generation.
Our sandwich ELISA results proved this proposal, the modulation of APPBP2/PAT1a
level not only affect the Aβ production but surprisingly favor particularly the
production of Aβ42. Thus, APPBP2/PAT1a is likely involved in the carboxy-terminal
cleavage of APP in both normal and pathological states.  Since there may be
different γ-secretaseprotein complexes involved in the generation of Aβ40 and Aβ42
(Klafki et al., 1996; Skovronsky et al,. 2000), it is interesting to speculate that
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elevated APPBP2/PAT1a may increase the ratio of Aβ42/Aβ40 by preferentially
encouraging the activity of the 42-specific γ-secretase, suggesting a function of
APPBP2/PAT1a in regulating  APP/APLPs in neurons.
4.7. Possible roles of interaction between APPBP2/PAT1a
and APP family proteins
It has been shown that in MDCK cells APP and APLP2 are transported to the
basolateral membrane (Haass et al., 1994; Lo et al., 1995) and in agreement with the
finding by Pimplikar and co-workers that the APPBP2/PAT1a binds to the BaSS of
APP, and with reference to data from our group that APPBP2/PAT1a also binds to
the BASS of APLPs. Thus APPBP2/PAT1a might be involved in subcellular targeting
of APP/APLPs. However, the molecular mechanisms underlying the APPBP2/PAT1a
function in subcellular sorting still remain to be investigated. Intriguingly, PAT1a was
recently identified as an androgen receptor (AR) associated protein, suppressing the
nuclear import of the AR (Zhang et al, 2004)The nuclear import of the AR depends
on homo-dimerization (Langley et al., 1995), implicating that the suppression of
nuclear import might be mediated by inhibition of the homo-dimerization of the AR.
APP was also shown to form homo-dimers, and the dimerization was shown to affect
processing (Scheuermann et al, 2001). A similar mechanism was proposed for
APLP1 and APLP2 (Scheuermann et al, 2001). Thus, it is reasonable that
APPBP2/PAT1a might suppress homo-dimerization of APP/APLPs, possibly causing
an altered subcellular transport to the cell surface or membrane compartments where
secretase activity and proteasomal cleavage occur, resulting in effects on
APP/APLPs proteolytic cleavages.
Furthermore, (i) a conformational change in the juxtamembraneouse intacellular
domain of APP/APLPs that contains the APPBP2/PAT1a-binding region, BaSS, or (ii)
an alteration in maturation of APP/APLPs caused by sorting variation, leading to
different membrane compartments, or (iii)an alteration of phosphorylation, or (iv)
either the binding capacity or the sorting change may facilitate proteasomal cleavage
of the cytosolic domain of APP so that altering gamma-secretase cleavage, or all of
above may occur when modulating the level of this binding partner, since all of above
possible roles have been proposed or shown in neurons with another intacellular
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domain binding partner of APP, Fe65 (Ando et al., 2001).
4.8. Conclusion and future views
Based on all the known knowledge of PAT1, and APPBP2/PAT1a shown in this
study, APPBP2/PAT1a widely overlaps with the expression pattern of APP, APLP1
and APLP2 and is predominantly expressed with relatively high level in the neurons
that located in the mouse brain regions where in human was shown severely affected
by AD in the brain. Further investigation of the expression of APPBP2/PAT1a and its
different polymorphisms on AD brains in comparison with normal samples will be a
necessary step to clarify this interpretation.
APPBP2/PAT1a exhibits structural similarity to KLC, associates with membrane
compartments in the late secretory pathway bearing APP/APLPs and interacts
directly with the BaSS of APP/APLPs in vitro. Further analysis of what have been
reported for the interaction between KLC and APP is necessary to clarify if
APPBP2/PAT1a is functionally similar to KLC and might compete the binding or
compensate the function of KLC in APP/APLPs transport. Although the BaSS has
been shown responsible for the sorting of APP, APLP2 to the basolateral surface in
polarized epithelial cells, no evidence has been shown that it may facilitate the
sorting to any particular subcellular region in neuronal cells. Variation of subcellular
distribution of APP/APLPs by APPBP2/PAT1a in neuronal cells thus likely depends
on other mechanisms instead of depending on the property of BaSS. Combination of
different analysis of APPBP2/PAT1a on possible influences such as the dimerization,
phosphorylation of APP/APLPs, shall be design to advance the knowledge toward its
physiological function.
Evidence is provided that APPBP2/PAT1a may alter the proteolytic conversion of all
APP family members and the ratio of Ab42/Ab40, indicating it may be a regulator of
the physiological function of the APP family members and might have an important
pathological role in AD. Further study will be necessary on whether the binding of
APPBP2/PAT1a to APP/APLPs changes the polarity when APP/APLPs vesicles
undergoes fusion to the plasma membrane, thus altering the secretase activity in
vitro. in vivo studies on mice with a deletion in the APPBP2/PAT1a gene crossed with
APP transgenic mice may address these questions and will be important for a more
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detailed understanding of the role of APPBP2/PAT1a in AD.
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5. Materials and Methods
5.1. Chemicals
Acetic anhydride Fluka
Agar Difco, Augsburg
Agarose Invitrogen
Amberlite Merck
6-Aminohexane acid Merck-Schuchardt, Hohenbrunn
Ampicillin Biomol, Hamburg
Ammoniumperoxodisulfate(APS) Roth, Karlsruhe
Bacto Tryptone Difco, Augsburg
Bacto Yeast Extract Difco, Augsburg
Benzonase Merck, Darmstadt
Bicinchinonic acid Sigma, Deisenhofen
Boric acid J.T.Baker, Deventer, Holland
Bovine serum albumne (BSA) Roth, Karlsruhe
Bromo-Chloro-Indolyl Phosphate (BCIP) Roche
Bromophenol-blue Serva, Heidelberg
Calciumchloride (CaCl2) J.T.Baker, Deventer, Holland
Coppersulfate (CuSO4) Sigma, Deisenhofen
CuSO4 solution (4%) Sigma, Deisenhofen
Dextransulfate Sigma
DMSO (Dimethylsulfoxide) Sigma, Deisenhofen
Disodiumhydrogenphosphate (Na2HPO4) Merck, Darmstadt
DTT (Dithiothreitol) Serva, Heidelberg
EDTA (Ethylendiaminetatracetate) Roth, Karlsruhe
Ficoll P-400 Amersham
Ethanol Riedel-de-Haen, Seelze
Ethidiumbromide Sigma, Deisenhofen
Formamid Merck
G418-sulfate PAA Laboratories
L-Glutamate acid Sigma, Deisenhofen
L-Glutamine (200 mM) Sigma, Deisenhofen
Glycerol Roth, Karlsruhe
Hydrochloric acid 37% Merck, Darmstadt
Hygromycin B PAA Laboratories
IPTG (Isopropylthiogalactoside) Biomol, Hamburg
Isopropanol Roth,Karlsruhe
Kanamycin Sigma, Deisenhofen
Levamisol Fluka
β-Mercaptoethanol Sigma, Deisenhofen
Methanol Merck, Darmstadt
Milk powder Roth, Karlsruhe
MOPS (3-(N-morpholine)propane sulfonic acid) Sigma, Deisenhofen
Natriumchloride (NaCl) J.T.Baker, Deventer, Holland
Nitroblue-Tetrazolium (NBT) Roche
Nonidet P40 (NP-40) Fluka, Neu-Ulm
Penicillin-Streptomycin Sigma, Deisenhofen
PMSF (Phenylmethylsulfonylfluoride) Serva, Heidelberg
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Poly-L-Lysine (PLL) Sigma, Deisenhofen
Polyoxyethylen-sorbitan-monolaurate( Tween20) Sigma, Deisenhofen
Polyvinylpyrrolidone Sigma
Protogel (30 % (W/V) Acrylamide;
0,8 %(W/V) Bisacrylamide) National Diagnostics
D(+)-Saccharose Roth, Karlsruhe
Sodiumazide (NaN3) Sigma, Deisenhofen
Sodiumdihydrogenphosphate (NaH2PO4) Merck, Darmstadt
SDS (Sodiumdodecylsulfate) Sigma, Deisenhofen
Sodiumpyruvate Sigma, Deisenhofen
Sucrose Sigma, Deisenhofen
TMEDA (N,N,N’,N’-Tetramethylenediamine) Sigma, Deisenhofen
Tricine Biomol, Hamburg
Triethanolamine (TEA) Fluka
Tris-HCl Sigma, Deisenhofen
Urea Roth, Karlsruhe
Xylene Sigma
5.2. Materials
1 kb (+) DNA-ladder Invitrogen
Phenobarbital sodium injection Abbott Laboratories
Antigen unmasking solution Vector
B27 supplement Invitrogen
Biomax MR single emulsion films Amersham (Kodak)
Bis-Tris-Gels 4-12% Invitrogen
BSA standard solution Pierce
Complete Protease Inhibitor Cocktail Roche Molecular Diagnostics
CSPD, ready to use Roche
3,3’-Diaminobenzidine Sigma Deisenhofen
Dulbecco’s Modified Eagle’s Medium (DMEM) Sigma Deisenhofen
DMEM/F-12 (1:1) Invitrogen
ECL solution Amersham
Expand Long Template PCR System Roche
F-12/HAM nutrient mixture Sigma, Deisenhofen
Fetal calf serum (FCS) PAA Laboratories or
Biochrom AG
Freund’s Adjuvant complete or incomplete Sigma, Deisenhofen
FuGene 6 Transfection Reagent Roche
Glutathione Sepharose 4 Fast Flow Amersham
Hepes Buffer (1M) Sigma, Deisenhofen
High Fidelity Polymerase Chain Reaction Mix Roche
Hyperfilm ECL Amersham
Human brain cDNA Clontech
Human MTNTM Blot BD Bioscience
In vitro transcription kit (DIG labeling) Roche
Lipofectamine Plus / Lipofectamine 2000 Invitrogen
[α32P]CTP 40 mCi/ml; Amersham
Mimimum Essential Medium Eagle (MEM) Sigma, Deisenhofen
Mouse Embryo MTNTM Blot BD Bioscience
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Mouse MTNTM Blot BD Bioscience
N2-supplement Invitrogen
Neurobasal Media Invitrogen
Nitrocellulose Protran 0,4 µm Schleicher & Schuell
Non-Essential Amino Acid Solution (100 x) Sigma, Deisenhofen
Normal sheep serum Dako
Nucleobond AX-Kit Macherey & Nagel
OPTI-MEM Invitrogen
Pfu-DNA-Polymerase Invitrogen
Prestained Protein marker: Rainbow low Amersham
Prestained Protein marker: Rainbow high Amersham
Prestained Protein Marker: Rainbow broad range Amersham
Protein A-Sepharose Amersham
ProFoundTM Co-Immunoprecipitation Kit Pierce
Qia Maxi Prep Kit Qiagen
Qia Spin Mini Prep Kit Qiagen
Qia Quick Gel Extraction Kit Qiagen
Quick Ligation Kit New England Biolabs (NEB)
Ouick Spin Columns Roche
RNAse free Proteinase K Roche
Sea-Blocking Pierce
SP6/T7 Transcription Kit Roche
StabilCoat SurModics
StreptABComplex/HRP DakoCytomation
Stratavidin-HRP Amersham
SulfoLink® Kit Pierce
T4-DNA-Ligase Invitrogen
Taq-DNA-Polymerase Invitrogen
1-StepTM Ultra TMB-ELISA Pierce
TOPO-cloning kit Invitrogen
Trypsin-EDTA Sigma, Deisenhofen
Yeast RNA Roche
**Restriction enzymes were purchased from Roche Molecular Diagnostics or New
England Biolabs (NEB).
**Cell culture dishes and flasks purchased from Sarstedt, Falcon, Costar, or Greiner.
**Plasticware was purchased from Sarstedt, Falcon, or Eppendorf.
5.3. Cell lines
DH5α: E. coli supE44 ΔlacU169 (80 lacZΔM15) hsdR17 recA1 endA1 gyrA96, thi-1
XL 1-Blue : E.coli Tn10 pro A+B+ lac/q Δ(lacZ)M15/recA1 endA1 gyrA96(Nal’) thi
         hsdR17 (rk
-mk
+) glnV44 relA1 lac
COS-7: African green monkey kidney epithelial cell line (Gluzman, 1981)
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SH-SY5Y: Human neuroblastoma (Ross et al., 1983)
HEK 293: Human embryonic kidney tumor, SV40-transformed
HeLa: Human epithelial adenocarcinoma cells from cervix
5.4. Antibodies
Name Protein(Epitope) WB IP (ul) IC/IH Reference
Anti-DIG-
AP
DIG,Fab
Fragments
- - 1:200 Roche
AP-20 MAP2 - - 1:400 Sigma
Anti-
PAT1a
hAPPBP2/PAT1a
(aa542-572)
1:500
(purified)
10
20
1:50 obtained from
Dr.S.Kins
22734 hAPP695
(ectodomain)
- 5 - obtained from
Prof. G.Multhaup
40090 hAPP695
(ectodomain)
1:8000 - - obtained from
G. Multhaup
42464 hAPLP1
(499-557 aa)
1:5000 - - (Ida et al., 1996)
42476 hAPLP2
(608-662 aa)
1:5000 - - Eggert et al. 2004
CT-11 hAPLP1
(640-650 aa)
1:10000 - 1:2000 Calbiochem
CT-12 hAPLP2
(752-763 aa)
1:10000 - 1:2000 Calbiochem
D2-II hAPLP2-751 1:10000 - 1:2000 Calbiochem
G2-10 Aβ 40 ELISA 5ug/ml (Ida et al., 1996)
G2-13 Aβ 42 ELISA 5ug/ml (Ida et al., 1996)
WO2-Biotin Aβ (1-16 aa) ELISA 1ug/ml - (Ida et al., 1996)
22C11 hAPP
(66-81aa)
1:10000 - - (Weidemann et
al., 1989)
3F10 rat αHA 1:5000 - 1:200 Roche
9E10 mouse αmyc - - 1:100 Roche
9E10 mouse αmyc - - 1:100 Santa Cruz
IB4 GFAP - - 1:200 BD Bioscience
SDL.3D10 β-Tubulin III 1:1.000 - - Sigma
TUB 2.1 β-Tubulin 1:1.000 - - Sigma
**For Enhanced Chemical Luminescence (ECL) detection after Western blotting,
appropriate Horseradish-Peroxidase (HRP) coupled anti-mouse (Promega), anti-
rabbit (Promega), or anti-rat (DAKO) antibodies were used as a 1:10.000 dilution.
**For immunocytochemistry, corresponding Alexa488, Alexa568, Alexa594, or
Alexa633 fluorescent dye-coupled, goat secondary antibodies were purchased from
Molecular Probes and used as a 1:200 dilution.
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**For Immunohistochemical stain with DAB detection, Biotinylated anti-rabbit
IgG(H+L) was used at dilution 1:200.
5.5. Plasmids
pCDNA 3.1(+)-Hygro Invitrogen
pCR II-TOPO Invitrogen
pcDNA3.1-V5/HIS6-TOPO Invitrogen
pSilencerTM 1.0-U6 siRNA vector Ambion
pCEP4-APP695, -APLP1, and -APLP2-2Z constructs have been previously
described (Eggert et al., 2004b) and have been kindly provided by S. Eggert. The
myc-APP, APLP1-, -APLP2 constructs were kindly obtained from Dr. Peter Soba.
5.6. Generation of PAT1, and PAT1a/APPBP2 Constructs
5.6.1. Primer selection
On the bases of the human PAT1 sequence information, primers were synthesized
flanking the coding region of human PAT1. All primers were synthesized by MWG
Biotech.
Primire name Sequence (5’ → 3’) Description
PAT1-5’-1 GAA GGA AGA TGG CGG CCG TGG hPAT1 mutagenesis
PAT1-3’-1 CCT CAG CAG CTC GGT CCC TCG ACA
TTC TG
hPAT1 mutagenesis
PAT1 150s GGA CGC TTA TGT CAA CTG sequencing
PAT1 150as CAG TTG ACA TAA GCG TCC sequencing
PAT1 391s CAG ATG CAG GCT GGT ACA sequencing
PAT1 391as TGT ACC AGC CTG CAT CTG sequencing
PAT1 709s CAG CAG GCT TAC CAG TGA sequencing
PAT1 709as TCA CTG GTA AGC CTG CTG sequencing
PAT1 979s TCC ACG TAG CAA CAG CTC sequencing
PAT1 979as GAG CTG TTG CTA CGT GGA sequencing
PAT1 1224s TTG CAC CTG TCT TCA CTC sequencing
PAT1 1224as GAG TGA AGA CAG GTG CAA sequencing
PAT1-Sub-S1 AAT TGG TAC CGC CGC CAC CAT GGC
GGC CGT GGA ACT AGA GTG
hPAT1 mutagenesis
inclu. Kozak seq.
PAT1-Sub-AS2 GTA ATT GCG GCC GCT CAA GCG TCT
TAG GGG ACG TCG TAT GGG TAG CAG
CAC GGT CCC TCG ACA TTC TG
hPAT1 mutagenesis
inclu. HA epitope.
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5.6.2. Amplification of PAT1orf by Polymerase Chain Reaction(PCR)
With consideration for AD researches, accurate genetic information from human brain
shall be an appropriate source, Human cDNA library obtained from Clontech was used
as a template to amplify our target protein PAT1.
Reaction Mixture                                 End.con.        Program steps
Template 1ng/ul 2 ul 40 pg/ul 94 ºC 2 min
10X PCR buffer 3 5 ul 1X 94 ºC 15 sec
dNTP Mix (12.5mM) 2 ul  500 uM 62 ºC 1 min       25X
PAT1-5’-1 (5pmol/ul) 4 ul 0.4 pmol/ul 68 ºC 2 min
PAT1-3’-1 (5pmol/ul) 4 ul 0.4 pmol/ul 68 ºC 7 min
 2d.H2O 32.25 ul 4 ºC ∞
Enzyme 0.75 ul 2.5 units
5.6.3. Generation of siPAT1a construct in pSilencerTM
For down regulation of PAT1a, the siPAT1a inserts were generated as described in
(Zhang et al., 2004) and subcloned into pSilencerTM 1.0-U6 siRNA Expression Vector
(Ambion).
5.7. DNA methods
5.7.1. Ethanol precipitation of DNA
Solutions: 3 M Sodium acetate pH 5.2
100 % Ethanol
70 % Ethanol
TE-buffer (pH 8.0): 10 mM Tris/HCl pH 8.0
1 mM EDTA pH 8.0
1/10 Vol. of 3 M Sodium acetate, pH 5.2 and 2.5 Vol. 100 % Ethanol (-20 °C) was
added to the DNA sample, mixed well, and incubated for 30 min at -20°C. The
precipitated DNA was centrifuged for 20 min at 4 °C/13.000 rpm, washed with icecold
70 % Ethanol, and centrifuged for 5 min at 4 °C/13.000 rpm. The supernatant was
removed, and the precipitated DNA was air-dried and diluted in TE-buffer or H2O.
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5.7.2. PCR (Polymerase chain reaction)
DNA was amplified by PCR using Taq, Pfu, or High Fidelity Taq/Pwo (Roche), as
appropriate. Specific sense and antisense oligonucleotide primers flanking the
desired target sequence were used.
A typical PCR reaction was prepared as follows:
10-100 ng DNA template
1 µl Polymerase (1 U)
5 µl 10 x reaction buffer
1 µl 10 mM dNTP (Desoxy-Nucleotide-Triphosphate)-Mix: (dATP, dTTP,
dGTP, dCTP)
2 µl sense-Primer, 10 pM
2 µl anti-sense-Primer, 10 pM
add 50   µl H2O
PCR parameters were adjusted to the appropriate conditions. Generally, 25-35
cycles were used for amplification.
5.7.3. Colony PCR
Colony PCR allows screening of a large number of transformed E. coli colonies for
positive clones before isolation from small scale cultures of these cells.
Colonies were picked with a sterile toothpick and dipped three times in 25 _l dd H2O.
To break the cell walls and release plasmid DNA, the mixture was boiled at 95°C for
5 min prior to the PCR. Taq-Polymerase, dNTPs, MgCl2, and buffer were added,
together with specific primers for the transformed plasmid. The PCR products were
analyzed on an agarose gel. In parallel, small scale liquid cultures were inoculated
with the colonies for isolation of plasmid DNA, and incubated on a shaker at 37° in
LB-medium containing the appropriate antibiotic for selection.
5.7.4. Restriction digestion of DNA
A typical reaction was prepared as follows:
1.0 µg DNA plasmid
3 µl 10x reaction buffer
0.5 – 1.0 µl Restriction enzyme (5-10 U)
ad 30 µl H2O
The reaction was incubated at the appropriate temperature (generally 37 °C) for
1-2 h.
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5.7.5. Analysis of DNA fragments on Agarose gels (Meyers et al., 1976)
Solutions: 1 x TAE buffer:
40 mM Tris-acetate
1 mM EDTA pH 8.0
Ethidiumbromide stock: 10 mg/ml (use 1:10.000)
6 x DNA sample buffer: 0.25 % (w/v) Bromophenol-blue
60 % Glycerol (w/v)
1mM EDTA pH 8.0
Depending on the size of the DNA fragments, appropriate 0.8-2 % (w/v) Agarose gels
were used for separation. The Agarose was dissolved in 1xTAE buffer by boiling in a
microvave oven. Ethidiumbromide was added to a final concentration of 1 µg/ml, and
the solution was poured into a gel chamber. Samples supplemented with DNA
sample buffer and, for comparison, a 1kb DNA ladder were loaded, and
electrophoresis was performed at 100-200V.
After separation, the gels were photographed and printed with a RAYTEST IDA
(Image and Documentation analysis) gel documentation device. The DNA fragments
were cut out from the gel under UV light (254 nm) and transferred into an Eppendorf
tube. To purify DNA fragments from agarose, the QIAquick gel extraction kit (Qiagen)
was used according to the manufacturer’s protocol. The DNA was eluted in 30 ul H2O
pH=8.4.
5.7.6. Ligation
A typical ligation reaction was prepared as follows:
300 ng DNA insert fragment
30 ng DNA vector fragment
4 µl 5x T4-DNA-Ligase buffer
1 µl T4-DNA-Ligase
ad 20 µl H2O
Insert DNA was generally used in a 5-10 fold excess of vector DNA. The ligation
reaction was incubated for 2-3h at 16°C.
Alternatively, the Quick Ligation kit was used according to the manufacturers protocol
(NEB). The ligation reaction was then incubated for 15-30 min at room temperature.
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5.7.7. Preparation of bactrial agar plates (Sambrook, 1989)
Solutions: LB-(Luria-Bertani) Medium: 
0,5 % (w/v) NaCl
1% (w/v) Bacto-Tryptone
0.5 % (w/v) yeast extract
20 mM Tris/HCl pH 7.5
The pH value was adjusted to 7.0 with NaOH.
2x YT-Medium: 1% (w/v) NaCl
1.6 % (w/v) Bacto-Tryptone
1% (w/v) yeast extract
20 mM Tris/HCl pH 7.5
The pH value was adjusted to 7.0 with NaOH
Bacto-Agar
Ampicillin stock (100 mg/ml): use 1:1.000
Kanamycin stock (50 mg/ml): use 1:1.000
For agar plates, 7.5g bacto-agar was added to 500 ml LB or 2xYT medium, and
autoclaved. After cooling to 60°C, the appropriate antibiotic was added to a final
concentration of 100ug/ml for Ampicillin or 50ug/ml for Kanamycin, respectively. The
liquid medium was poured into 10 cm culture dishes and allowed to cool to room
temperature. The agar plates were stored upside down at 4°C and covered from
light.
5.7.8. Chemo-competent E. coli generated with the RbCl method
RFI buffer:    100 mM RbCl
50 mM MnCl2 x 4 H2O
30 mM Potassium acetate
10 mM CaCl2 x 2 H2O
15 % Glycerol (w/v)
The pH value was adjusted to 5.8 with acidic acid. The buffer was sterile filtered, and
50 ml aliquots were stored at -20 °C.
RFII buffer: 10 mM MOPS (3-(N-Morpholino)-propanesulfonic acid)
10 mM RbCl
75 mM CaCl2 x 2 H2O
15 % Glycerol (w/v)
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The pH value was adjusted to 6.8 with NaOH. The buffer was sterile filtered, and
15 ml aliquots were stored at -20 °C.
SOB-Med.: 20 g Bacto-Tryptone
5 g Bacto-yeast extract
0.5 g NaCl
add 1L dd H2O
The components were dissolved and 10 ml of a 250mM KCl solution were added.
The pH value was adjusted to 7.0 with NaOH and the water was added to a final
volume of 1L. Immediately before use, 5 ml of a 2M MgCl2
 solution were added.
SOC-medium: identical to SOB-medium; additionally, 20 ml of a 1 M sterile filtered
Glucose solution were added before use.
A single colony (E. coli DH5α) was inoculated into 2 ml SOC-medium and incubated
for 2h at 37°C under vigorous shaking. Afterwards, 500ul were inoculated into 50 ml
SOB-medium and incubated at 37°C, until an OD (600 nm) ~0.5-0.6 was reached.
The following steps were conducted at 4 °C with pre-cooled material. The culture was
transferred to 50 ml Falcon tubes and incubated for 15 min at 4 °C, and centrifuged
at 3000rpm/4 °C (Heraeus centrifuge) for 10min. The sedimented cells were
resuspended in 17 ml RFI buffer and incubated on ice for 30min. The cells were
again centrifuged at 3000rpm/4°C (Heraeus centrifuge) for 10min, resuspended in
4 ml RFII buffer, and incubated on ice for 15min. Aliquots of 200ul were transferred
into Eppendorf tubes and shock frozen in liquid nitrogen. Competent DH5α were
stored at -80°C.
5.7.9. Transformation of chemo-competent E. coli
LB-medium
Chemo-competent DH5α
Bacterial agar plates
Chemo-competent cells were treated according to (Hanahan, 1985). Cells were
thawed on ice, and DNA (5-200ng) was added to a 100ul cell aliquot, and incubated
for 15 min on ice. Cells were heat shocked for 45-60 s at 42°C, and cooled on ice for
5 min. 900ul LB medium were added and cells were incubated for 45-60min at 37°C
on a roller shaker. Afterwards, different aliquots were plated on bacterial agar plates
(50-500ul) and incubated over night at 37°C.
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5.7.10.  Liquid cultures of bacteria
LB medium
Small scale liquid cultures
A single colony was inoculated into 2-3ml LB medium supplemented with the
appropriate antibiotic, and incubated over night at 37°C under vigorous shaking. The
bacterial culture was used for small scale DNA preparation (Mini Prep).
Large scale liquid cultures
For large scale DNA preparation (MaxiPrep), a 1 ml pre-culture was inoculated into
200 ml LB-medium supplemented with the appropriate antibiotic, and incubated over
night at 37°C under vigorous shaking.
5.7.11.  Small scale DNA preparation (Mini Prep)
For small scale DNA preparation (1-5 ug), the Qiagen MiniPrep Kit was used.
Buffers were supplied by Qiagen
S1: 50 mM Tris/HCl, 10 mM EDTA, 100 µg RNase A / ml, pH 8.0
S2: 200 mM NaOH, 1% SDS
S3: 2.80 M Potassium acetate pH 5.1
70 % Ethanol
TE-buffer pH 8.0: 10 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.0
Small scale liquid cultures (1-2 ml) were transferred into an Eppendorf tube and
centrifuged at 6000rpm for 5 min. Cells were resuspended in 100 ul S1 buffer and
further processed according to the manufacturer’s protocol.
5.7.12.  Large scale DNA preparation (Maxi Prep)
For large scale DNA preparation (200-500 ug), the Qiagen Maxi Prep kit, or the
Nucleobond AX-500 kit (Macherey & Nagel) were used.
S1: 50 mM Tris/HCl, 10 mM EDTA, 100 µg RNase A/ml pH 8.0
S2: 200 mM NaOH, 1% SDS
S3: 2.80 M Potassium acetate pH 5.1
N2: 100 mM Tris, 15 % Ethanol and 900 mM KCl pH 6.3
N3: 100 mM Tris, 15 % Ethanol und 1150 mM KCl pH 6.3
N5: 100 mM Tris, 15 % Ethanol und 1000 mM KCl pH 8.5
Isopropanol p.a.
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3M Sodium acetate pH 5.2
100 % Ethanol p.a. (-20°C)
70 % Ethanol p.a. (-20°C)
TE-buffer pH 8.0: 10 mM Tris/HCl pH 8.0, 1 mM EDTA pH 8.0
A large scale bacterial culture was centrifuged for 10 min at 6000 rpm/4°C
(Beckmann JA-2, rotor JA 10-158). Cells were resuspended in 12ml S1 buffer and
further processed according to the manufacturer’s protocol. For low copy plasmids,
double buffer amounts were used.
Further, the DNA precipitated with Isopropanol was dissolved in 500ul H2O and
precipitated again with Ethanol as described. After centrifugation, the precipitated
DNA was washed with 70% Ethanol once and centrifuged for 5 min at 13.000 rpm.
The DNA pellet was air-dried and dissolved in TE-buffer or H2O.
5.7.13.  Photometric analysis of DNA concentrations
Concentrations of DNA were measured with a spectral photometer (Biorad Smart
Spec 3000) at a wavelength of 260 nm. Generally, the DNA was diluted to 1:100 in
H2O for measurement.
A rule of thumb: ssDNA or ssRNA: A260nm(1cm)= 1 c ~ 40 µg/ml
dsDNA: A260nm(1cm)= 1 c ~ 50 µg/ml
The purity of the DNA samples was determined by measuring the A280nm and A310nm,
which correspond to the absorption maxima of proteins and polysaccharides. For
pure DNA, the A260nm/A280nm ratio is supposed to be between 1.8 and 2.0, with no
absorption at A310nm.
5.7.14.  Phenol-chloroform extraction of DNA
An equivalent volume of Phenol-Chloroform-Isoamylalcohol (25:24:1) was added to a
DNA solution in TE buffer or H2O, and thoroughly vortexed for at least 1 min. The
emulsion was centrifuged for 10 min at 14.000xg to achieve a separation of the
phases. The aquatic, DNA containing phase on top was carefully transferred into a
new Eppendorf tube. The procedure was repeated once, and the DNA was
precipitated with Ethanol as described and dissolved in TE-buffer or H2O.
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5.8. Northern Analysis
Northern analysis. Blots with samples from different tissues and developmental
stages obtained from human and Balb/c mice were purchased from Clontech.
Experiments were performed under the User Manual
5.8.1. Probe synthesis, 32P labeling and Alkaline Hydrolysis
Full-length random 32P-labeled cRNA probes were synthesized by using SP6/T7
Transcription Kit (Roche) following the instruction manual. Alkaline hydrolysis was
done at 65°C, 12min. this should bring the probe length ∼500bp
5.8.2. Count of radioactivity on synthesized probes
Measuring the radioactivity with counter and apply 32P >1x106 cpm/ml to the
membrand for hybridization.
5.8.3. Hybridization and Washing
*Add the 15 ml of RNA probe-containing hybridization Buffer to the hybridization
tube, avoid air bubbles and cap it.
*Incubate with gentle rocking for o/n at 42°C.
5.8.4. Capture of radioactive signals
Autoradiography was done with exposing the blot to Biomax MR films (Kodak) at -70
°C for at least 20 hrs.
5.8.5. Striping and storage of MTN Blots
To reprobe the Northern blot, shake the membrane slowly in Stripping Buffer
0.1%SDS in 2XSSC for 10min at 90°C. Then, shake vigorously for 15 min at room
temperature in 2 X SSC/0.1% (w/v) SDS.
5.8.6. Generation of control β-actin probe
Human β-actin orf was amplified by PCR and TA-cloning into pCRII-TOPO vector.
Probe thynthesis was done by using the same kit which was used to generated the
APPBP2/PAT1a cRNA probe.
5.9. In situ Hybridization Analysis
9-12 month-old wild type mice (C57Bl6) brain sections were prepared as described in
(19). Hybridization procedures were done by reference to the published protocols
(20) and performed with random DIG-labeled alkaline hydrolyzed full-length
APPBP2/PAT1a cRNA probes (->500bp). Signals were visualized with alkaline
phosphate system (Roche), Image acquisition was performed with Olympus BX60,
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Coupled CCD camera (Olympus), and program Studio Lite (Pixera).
5.9.1. Buffers
3M Natriumacetat pH=5.2
10X PBS: 137mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2mM KH2PO4
50X Denhard’S: Ficol 1g, PVP 1g, BSA Fraction 1g
in 10ml ddH2O
20XSSC: 3M NaCl, 0.3M Na-citrate
1M Levamisol
0.1M TEA
10% Triton X-100
Buffer 1: 100mM Tris-HCl pH=7.5, 150mM NaCl
Buffer 2: 100mM Tris-HCl pH=9.5, 100mM NaCl
Buffer 3: 10mM Tris-HCl pH=8.1, 1mM EDTA
5.9.2. Transcadiac perfusion for tissue fixation
9-12 month-old wild type mice (C57Bl6) were anesthetized with 0.1 ml Pentobarbital
Sodium sol. and transcaeiac perfused with 300ml 1XPBS, 300ml ice-cold 4%PFA,
using 23G needle and perfusion pump set speed15ml/min.
5.9.3. Brain removal and Paraffin embedding
4% PFA fixed mice brains were removed and proceeded to post-fixation at 4°C for 4
hr with shaking. Paraffin embedding were done with HypercenterXP embedding
machine and follwing the intruction manual.
5.9.4. Sectioning, De-wax and Rehydration
Sections were cut in 7um thickness and place onto PLL coted glass slides. Dry slide
in an oven 52°C overnight. Dewaxed with fresh Xylene 2X 10 min at RT. Rehydrated
as following:
100% EtOH 5min
95% EtOH 5min
70% EtOH 5min
50% EtOH 5min
1XPBS 5min x 2
5.9.5. Probe synthesis, DIG labeling and Alkaline Hydrolysis
Probes were thynesized by DIG- RNA labeling kit (Roche) following the instruction
manual. Alkaline hydrolysis was done at 65°C, 12 min, and stopped by adding 1/20
0.5mM EDTA.
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5.9.6. Measurement of DIG amount on synthesized probes
Measurement of DIG amount along with the synthesized cRNA probes was
performed by using CSPD kit as following the instruction manual.
5.9.7. Section pretreatments and Hybridization Procedures
Continuing the 5.9.6. and proceeding as following:
post fixation with 4%PFA 10min RT
Wash with 1X PBS 5min x 3
0.1M HCl  10 min
wash with 1X PBS min x 3
Proteinase K (10ug/ml) treatment at 37°C, 10 min
Wash with 1X PBS 5 min x 3
0.1M TEA 45ml + 750 acetic anhydride 20min
Wash with 1X PBS 5min x 3
Calculate dilution factors by CSPD measurement result and dilute the
cRNA probes in hybridization buffer
Denature at 85°C 10 min
hybridization at 42°C overnight
5.9.8. Detection of DIG signals
wash with Buffer 1  5min x 3
Incubate with blocking sol.(buffer1+ 5% NSS) 30 min, RT
Wash with Buffer 1  5min x 3
Incubate with anti-Dig 1:200 in buffer 1 + 2% NSS, 1 hr RT
Wash with Buffer 1  5 min x 3
Incubate with Buffer 2 10 min RT
Incubate with detection sol. (20 ul NBT/BCIP in 5ml Buffer2),
-optimalzed by individual experiment
Stopped with Buffer 3
Wash with dd H2O 5min x 3
5.9.9. Mount sections and Image Acquisition
Sections were mounted with Mowil sol. and proper size coverslips. Image acquisition
was performed with Olympus BX60, Coupled CCD camera (Olympus), and program
Studio Lite (Pixera).
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5.10. Generation of polyclone rabbit anti-PAT1a/APPBP2
antibodies
5.10.1. Selection of sequence-specific residue on APPBP2/PAT1a
5.10.2. Peptide synthesis
Selected sequence: Anti-PAT1ct: at position 541-573,
-CKWNRLRDRQYSVTDALEDVSTSPQSTEEVVQ-
The peptide was synthesized by Peptide Speciality Laboratories GmbH
Coupled peptide with KLH was done by using KLH coupling kit (Pierce)
5.10.3 Immunorization
Injection of the anti-PAT1a peptide was performed by animal facillity of ZMBH, every
2 weeks.
5.10.4. Anti-Serum collection
Following 7 days after every injections, 15 ml anti-serum were collected and
centrifuged at 5000 rpm, 4°C, 15 min. The upper phase (serum) were collected and
aliqued 0.5 ml for long term storage.
5.10.5. Affinity screen by BIACore Surface Plasmon Resonance (SPR)
Surface plasmon resonance is a phenomenon which occurs when light is reflected off
thin metal films. A fraction of the light energy incident at a sharply defined angle can
interact with the delocalised electrons in the metal film (plasmon) thus reducing the
reflected light intensity. The precise angle of incidence at which this occurs is
determined by a number of factors, but in the Pharmacia BIA devices the principal
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determinant becomes the refractive index close to the backside of the metal film, to
which target molecules are immobilised and addressed by ligands in a mobile phase
running along a flow cell. If binding occurs to the immobilised target the local
refractive index changes, leading to a change in SPR angle, which can be monitored
in real-time by detecting changes in the intensity of the reflected light, producing a
sensorgram. The rates of change of the SPR signal can be analysed to yield
apparent rate constants for the association and dissociation phases of the reaction.
The ratio of these values gives the apparent equilibrium constant (affinity). The size
of the change in SPR signal is directly proportional to the mass being immobilised
and can thus be interpreted crudely in terms of the stoichiometry of the interaction.
Signals are easily obtained from sub-microgram quantities of material. Since the SPR
signal depends only on binding to the immobilised template, it is also possible to
study binding events from molecules in extracts; i.e. it is not necessary to have highly
purified components.
Surface plasmon resonance detection unit. L: light source, D: photodiode array, P:
prism, S: sensor surface, F: flow cell. The two dark lines in the reflected beam
projected on to the detector symbolise the light intensity drop following the resonance
phenomenon at time = t1 and t2. The line projected at t1 corresponds to the situation
before binding of antigens to the antibodies on the surface and t2 is the position of
resonance after binding.
5.11. Cell Cultures and Transfections
5.11.1. Preparation of culture mediums
COS-7 & Hela: 10% FCS in DMEM+ 1%P/S
SH-SY5Y: F12 250ml+MEM 250ml+L-Glutamine 6ml+P/S 6ml
+Non.Essential aa. 6ml+10%FCS+1&P/S
HEK293: 10%FCS+0.1%Non-Essential aa.+1%P/S in DMEM
5.11.2. Maintainace of cell lines
Freezing of cells for long term storage
Freezing medium: 10 % (v/v) DMSO in growth medium with 20 % FCS and w/o
antibiotics
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Cells at 70-90 % confluency were used for freezing. Cells from a 10 cm dish were
trypsinized as described and transferred into 15 ml tubes with 10 ml of fresh medium.
The cells were sedimented at 300x g for 5 min and resuspended in 3-4.5 ml freezing
medium. 1.5ml aliquots were transferred into cryovials (Nunc), and incubated on ice
for 1-1.5 h. The vials were then stored at -80 °C over night, and then transferred into
a liquid nitrogen tank for long term storage.
Alternatively, vials were directly incubated in a cryobox (Nunc) containing
Isopropanol at 80°C over night, and afterwards transferred into a liquid nitrogen tank
as well.
Thawing of frozen cells
Cells frozen in liquid nitrogen were quickly thawed at 37 °C in a water bath. Cells
were then transferred into a 10 cm dish with 10 ml fresh growth medium and equally
distributed with gentle shaking. The medium was replaced the next day to remove
residual DMSO.
Alternatively, thawed cells were transferred into 15 ml tubes with 10 ml of fresh
medium and centrifuged at 300x g for 5 min. The cells were resuspended in 5 ml
normal growth medium, and transferred to 10 cm culture dishes with 10 ml of fresh
growth medium. Cells were further cultured as described.
5.11.3. Transfection methods used in this study
Transfection of COS-7, HEK293 and HeLa cells with Lipofectamine Plus
OptiMEM (Invitrogen)
Lipofectamine Plus (Invitrogen)
Fatal calf serum (FCS)
Generally, 6cm dishes with cells at 80-90 % confluency were transfected. In an
Eppendorf tube, 2ug DNA were mixed with 250 ul OptiMEM and 15ul Plus reagent.
After 15 min incubation, 5µl Lipofectamine in 250ul OptiMEM were added, inverted
several times, and incubated for 15min.
Cells were washed with OptiMEM once and 2 ml OptiMEM were added. The
Lipofectamine/DNA mixture was added dropwise to the cells and incubated for 3-4 h
at 37°C and 5 % CO2. Afterwards, the reagent was removed and fresh normal growth
serum was added. After 24h, the cells were either harvested for analysis or passaged
and selected for stable expression. For this purpose, the growth medium was
supplemented either with 500 µg/ml G418 or 250 µg/ml Hygromycin, depending on
the transfected plasmid. The cells were further cultivated as described.
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Transfection of SH-SY5Y cells with FuGene 6
OptiMEM (Invitrogen)
Lipofectamine (Invitrogen)
Plus-reagent (Invitrogen)
In an Eppendorf tube, 5ug DNA were mixed with 750ul OptiMEM and 20ul Plus
–reagent. After 15min incubation, 30ul FuGene6 in 750ul OptiMEM were added,
inverted several times, and incubated for 15min. A 10cm dish with SH-SY5Y cells at
70-80 % confluency was washed with 1x PBS twice and 5 ml OptiMEM were added.
The FuGene6/DNA mixture was added dropwise to the cells and incubated for 3h at
37°C and 5 % CO2. Afterwards, 5ml OptiMEM and FCS to a final concentration of
10% were added. The next day, appropriate growth medium containing either 500
µg/ml G418 or 250 µg/ml Hygromycin, depending on the transfected plasmid, was
added to select transfected cells for stable expression. The cells were further
cultivated as described.
5.12. Western Analysis
5.12.1. Collection of cell and tissue lysates
Cell lysis
1x PBS
Lysis buffer: 50 mM Tris pH 7.4
150 mM NaCl
2 mM EDTA
1 % NP-40
Complete Protease Inhibitor Mix (Roche)
2x SDS sample buffer
Cells were washed once with cold PBS, scraped in 500 ul 1x PBS, and transferred
into an Eppendorf tube. Residual cells in the dish were scraped again in 500 ul
1x PBS, and transferred into the same tube. Cells were centrifuged at 300x g for
5 min, the PBS was removed, and an appropriate amount (50-500 ul) of cell lysis
buffer supplemented with Complete Protease Inhibitors was added. Cells were
resuspended in the lysis buffer and incubated for 20 min on ice. The lysate was
cleared from debris and nuclei by centrifugation at 16.000x g for 10 min. The
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supernatant was used immediately for immunoprecipitation, or denatured with the
appropriate amount of 2x SDS sample buffer. Alternatively, cell lysates were stored
at -80°C for later use.
5.12.2. Measurement of protein concentration
BioRad DC protein assay (Biorad)
Bicinchoninic acid (BCA) (Sigma)
4% CuSO4 solution (Sigma)
BSA (Bovine Serum Albumin) standard solutions (0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8,
1.0 mg/ml).
ELISA 96-well plate (Greiner)
The protein concentration of lysate supernatants was determined using the BioRad
DC protein assay (Biorad) or a BCA assay (Sigma) according to the manufacturer´s
protocol.
The BioRad DC protein assay is based on a Lowry assay (Lowry et al., 1951), where
proteins react with an alkaline copper tartrate solution and reduce the added folin
reagent. The reduced folin species have a characteristic blue color with an
absorption maximum of 750 nm.
The BCA assay is based on a quantitatively catalyzed reaction of the BCA-Cu2+-
complex to the reduced BCA-Cu+-complex, which is accompanied by a color change
with an absorption maximum at 550 nm.
For the BCA assay, 20ul of each BSA standard solution and cell lysate (1:10 dilution)
were pippeted into the ELISA plate in triplicates. The 4 % CuSO4 solution was diluted
1:40 with the BCA solution, and 200ul of the mixture were added to the standards
and lysates. The plate was incubated for 15 min at 37°C, and further 15 min at room
temperature on a horizontal shaker.
Absorption was measured with a microplate-reader (BIO-RAD, model 450) at
550 nm, and protein concentrations were calculated with the BSA standard curve.
5.12.3. Preparation of SDS-PAGE
Discontinous SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)
Tris-Tricine gels were prepared according to (Laemmli, 1970).
Buffers: 30 % (w/v) Acrylamide; 0.8 % (w/v) Bisacrylamide (Protogel)
separation gel buffer: 2 M Tris/HCl, pH 8.8
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Stacking gel buffer: 1 M Tris/HCl, pH 6.8
20 % (w/v) SDS (Sodium dodecylsulfate)
10 % (w/v) APS (Ammoniumperoxodisulfate)
TMEDA
1 x running buffer: 25 mM Tris-base, 192 mM Glycine, 0.1 % SDS
Separating gel:
Gel
percentage
Protogel
(ml)
2 M Tris,
pH 8.8
(ml)
20 %
SDS
(ml)
ddH2O
(ml)
10 % APS
(ml)
TMEDA
(ml)
Final
volume
(ml)
15 % 15 5.6 0.15 9.1 0.1 0.02 30
8 % 8 5.6 0.15 16.1 0.1 0.02 30
Stacking gel:
Protogel
(ml)
1 M Tris,
pH 6.8
(ml)
20 % SDS
(ml)
ddH2O
(ml)
10 % APS
(ml)
TMEDA
(ml)
Final
volume
(ml)
1.67 1.25 0.05 7.00 0.05 0.015 10.035
Elektrophoresis was performed over night at 70-90 V.
Precut glass plates (20 x 20 cm) were assembled with Teflon spacers (1 mm) and a
silicon tube and used for casting the gel.
Tris-Tricine-PAGE
Tris-Tricine gels were prepared according to (Schagger and von Jagow, 1987).
Cathode buffer: 0.1 M Tris, 0.1 M Tricin, 0.1% SDS
Anode buffer:  0.2 M Tris/HCl pH 8.9
Gel buffer: 3 M Tris, 0.3 % SDS, pH 8.45
Stacking
gel
4% T
3 % C
Separating
gel
10 % T
3 %C
Separating
gel
16.5 % T
3 % C
Separating
gel
16.5 % T
6 % C
49,5 % T solution
3 % C solution
1 ml 6.1 ml 10 ml -
49,5 % T solution
6 % C solution
- - - 10 ml
Gel buffer 3.1 ml 10 ml 10 ml 10 ml
Glycerol - 4 g 4 g 4 g
ad H2O 12.5 ml 30 ml 30 ml 30 ml
10 % (w/v) APS 150 µl 150 µl 150 µl 150 µl
TMEDA 20 µl 20 µl 20 µl 20 µl
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[T = Acrylamide; C = Bisacrylamide]
Alternatively, for separation of small molecular weight proteins, precast 10-20 % Tris-
Tricine gels (Invitrogen) were run with 1x cathode buffer for 90 min at 140 V.
Bis-Tris-HCl polyacrylamide gel electrophoresis
Separation of proteins by electrophoresis was also carried out using precast 4-12 %
Bis-Tris gels (Invitrogen).
20 x MES buffer: 1 M MES, 1 M Tris base, 69.3 mM SDS, 20.5 mM EDTA
20x MOPS buffer: 1 M MOPS, 1 M Tris base, 69.3 mM SDS, 20.5mM EDTA.
Depending on the molecular weight of the protein of interest, 1x MOPS (50-100 kDa)
or 1x MES (10-50 kDa) running buffer were used due to different separation
properties.
5.12.4. Transfer of proteins on to Nitrocellulose Membrane
Proteins separated by SDS-PAGE were transferred from the gel to a nitrocellulose
membrane by electrophoresis (Western blotting).
Cathode buffer: 25 mM Tris base, 40 mM 6-Aminohexane acid, 20 % Methanol
Anode buffer I: 30 mM Tris base, 20 % Methanol
Anoden buffer II: 300 mM Tris base, 20 % Methanol
Nine sheets of Whatman paper were cut according to the gel size and three sheets
were soaked with each buffer. A nitrocellulose membrane was also presoaked in
Anode I buffer. The blot was assembled on a semi-dry apperature as follows:
Cathode (-)
3 Whatman sheets soaked with cathode buffer
SDS gel
Nitrocellulose soaked with Anode I buffer
3 Whatman sheets soaked with anode I buffer
3 Whatman sheets soaked with anode II buffer
Anode (+)
The proteins were blotted for 1-1.5 h at 1 mA/cm2.
5.12.5. Western blotting (wet blot)
Transfer buffer: 192 mM Glycin, 25 mM Tris-Base, 20 % Methanol
Following SDS-PAGE, the gel was equilibrated in transfer buffer for 5 min. Whatman
sheets and a nitrocellulose membrane were cut to the size of the gel and soaked in
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transfer buffer. The gel and the membrane were sandwiched between soaked pieces
of sponge pads, Whatman paper, and perforated plastic plates as follows:
Anode (+)
Sponge pad
2 Whatman sheets
Nitrocellulose
SDS gel
2 Whatman sheets
Sponge pad
Cathode (-)
The transfer was performed in a blotting tank (Biorad) for 1-3 h at 380 mA at 4°C.
5.12.6. Signal detection by Enhanced Chemo-lumicent system
10x PBS
10x TBST (Tris buffered saline Tween): 100 mM Tris/HCl
1.5 M NaCl
0.5 % Tween 20
ECL-Kit (Amersham)
After western blot transfer of the proteins to the nitrocellulose membrane, the
membrane was blocked for 1 h in 1x TBST/5 % (w/v) skimmed milk. The primary
antibody was diluted in 1x TBST to an appropriate concentration and the blot was
incubated either for 2-4 h at room temperature or overnight at 4 °C. The membrane
was washed twice with 1x TBST, and further incubated two times in 1x TBST for
10 min. Incubation of the blot with the secondary antibody conjugated to horseradish
peroxidase (HRP, dilution 1:10.000) was carried out for 1 h at room temperature. The
membrane was again washed twice with 1x TBST, and further incubated two times in
1x TBST for 10 min. The protein of interest was detected by enhanced chemical
luminescence (ECL) utilizing the reaction of Luminol and H2O2, which is catalyzed by
HRP. For this purpose, the membrane was incubated with the ECL (Amersham)
reagent for 1 min and the chemifluorescent signal was visualized by exposure of
Hyperfilm ECL (Amersham) films.
5.12.7. Reprobing of Western blot membranes
Stripping buffer: 62.5 mM Tris/HCl pH 6.7
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100 mM β-Mercaptoethanol
2 % SDS
For reprobing the membrane with different antibodies, the previously applied
antibodies had to be removed first. For this purpose, stripping buffer was preheated
to 80 °C. The membrane was incubated with 100-200 ml preheated stripping buffer
on a horizontal shaker until room temperature was reached (30-45 min). The
membrane was further incubated several times with 1x TBST, until no residual
β-Mercaptoethanol could be detected (3-5 times). The blot was again blocked in
1x TBST/5 % (w/v) skimmed milk for 1 h, and a new primary antibody could be
applied as described.
5.13. Immunohistochemical Stain
Brains from 9 to 12-month-old wild-type (C57Bl6) and APLP1-/- mice were used.
Animals were prepared the same as described in (19). After the post fixation, paraffin
sections were treated with Antigen Unmasking Solution (Vector Laboratories).
Neurons were fixed with 4% PFA and permeabilized with 0.1%NP-40/PBS. The
staining was performed using the published procedures (22). For DAB detection,
StreptABComplex/HRP kit (DAKO Diagnostic) was used. Image acquisition of DAB
signals were performed the same as described in the ISH. The fluorescent signals
were visualized with the Axiovert 200M Inverted Microscope (Zeiss), supplied with
CCD Camera (Hamamatsu) and images were acquired and enhanced using the
MetaMorph Imaging System (Universal Imaging Co.).
5.14. Culture and transfection of Mouse embryonic cortical
neurons
5.14.1. Preparation of culture mediums
Neurobasal+Glutamate culture medium: neurobasal medium 200 ml, B-27
supplement 4 ml, 200mM L-Glutamin 500 ul, 25 mM Glumate 200 ul
Neurobasal-Glutamate culture medium: neurobasal medium 200 ml, B-27
supplement 4 ml, 200mM L-Glutamin 500 ul
10X HBSS
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5.14.2. Animal and tissue preparation
Mouse was anesthetized with overdosed CO2, then E14 brain were removed and
placed in 10cm-dish with proper amount of 1X HBSS. Isolated embryonic cortexs
were trypsinized at 37°C 15 min. Wash with 1X HBSS 5 times, plate into desired
sized dishes, cultured with Neurobasal+Glutamate culture medium.
5.14.3. Transfection procedures
Thansfection of primary neurons in this study were all done by using
Lipofectamine2000 and following with the instruction manual.
5.15. Immunocytochemical Stain
5.15.1. Fixation of cells
Cells expressing APPBP2/PAT1a-HA or co-expressing with APP family proteins,
myc-APP, APLP1-myc, and myc-APLP2, were grown on cover slips, harvested and
fixed with 4% Paraformaldehyde in 1xPBS for 10-30 min.
5.15.2. Staining procedures
Cells were permeabilized in 1x PBS + 0.1% Triton X-100 for 15 min and blocked with
5% normal goat serum in 1x PBS for 1h. Incubation with primary antibody over night
at 4°C. The next day, cells were incubated with the appropriate secondary antibodies
coupled to Alexa 488 and Alexa 594 fluorescent dyes (Molecular Probes) for 1h at
room temperature, and mounted in Mowiol. Omission of primary antibodies was used
as a control to verify specificity and showed only very low background staining.
5.15.3. Signal Visualization and Image acquisition
The fluorescent signals were visualized with the Axiovert 200M Inverted Microscope
(Zeiss) supplied with CCD Camera (Hamamatsu), and images were acquired and
enhanced using the MetaMorph Imaging System (Universal Imaging Co.).
5.16. Immunoprecipitation and Co-Immunoprecipitation
5.16.1. Buffer preparation
Washing buffer A (Wash A): 10 mM Tris/ HCl pH 7.5
150 mM NaCl
5mM EDTA
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0.2 % NP40
Washing buffer B (Wash B): like Wash A, but with 500 mM NaCl instead
Washing buffer C (Wash C): 10 mM Tris/HCl pH 7.5
2x SDS sample buffer
5.16.2. Coupling antibodies to Agarose beads
Coupling of anti-PAT1a antibody to sepharose beads by using ProFund co-
Immunoprecipitation Kit (Pierce) were done with following the instruction manual.
5.16.3. Procedures
Protein A sepharose (Amersham) as a 50 % slurry in Wash A, 0.02% NaN3
If not stated otherwise, proteins from brain or cell lysates were precipitated with
appropriate antibodies and 30 ul ProteinA beads. Medium aliquots were cleared from
cell debris by centrifugation at 15000xg for 10min. Protein lysates (minimum sample
volume was 500ul) were generally preincubated for 1h at 4°C with 10ul of ProteinA
sepharose to reduce unspecific binding. Equally, antibodies were prebound to 30ul of
ProteinA sepharose in 500ul Wash A by incubating on an overhead shaker for 1h at
room temperature. The sepharose beads were sedimented at 15000xg for 30s, and
the cell lysate supernatant was transferred to the prebound antibody beads. The
samples were incubated for 23 h at room temperature, or over night at4 °C. The
sepharose beads were centrifuged at 15000xg for 30s, and washed three times with
Wash A buffer. In case of unspecific binding, additional washing steps with Wash B
and Wash C were performed. The buffer was completely removed with a Hamilton
syringe, and the Sepharose beads were denatured in 2x SDS sample buffer for
10min at 95°C. The samples were further analyzed by SDS-PAGE and Western
blotting.
5.17. ELISA
5.17.1 Buffers
Carbonate Buffer: 25 mM Na2CO3, 75 mM NaHCO3 in 1000 dd H2O
10X Wash Buffer: 9.5 mM NaH2PO4xH2O, 6.8 mM Na2HPO4x2H20,
137 mM NaCl, 1% (v/v) Tween 20 in 1000 ml dd H2O
10X PBS (80mM): 9.5 mM NaH2PO4xH2O, 6.8 mM Na2HPO4x2H20,
137 mM NaCl
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Liquor Buffer: 1.5 % BSA, 0.5% Tween 20, 100ml 80 mM PBS
HRP Buffer: 0.1% BAS, 0.1%(v/v) Tween 20 in 100 ml 80 mM PBS
Stop solution: 1M H2SO4
5.17.2. Procedures
Coating capturing antibodies:
G2-10 85ug/ml), G2-13 (5ug/ml) in 110ul Carbonate Buffer/well
Incubate at 37°C 2hr
Wash with wash buffer 5min x 3
Blocking with StabilCoat (SurModics) 110ul/well Rt 2hr
Wash with wash buffer 5min x 3
Preparing reaction mixture:
WO2-Biotin 1:1000 in 50 ul Liquor buffer+
10% Sea-Blocking buffer(Pierce) / well
50 ul sample ( for Aβ 40 1:5 diluted, for standard
1:10 diluted) / well
Incubate at 4 °C 48 hr
Wash with 250 ul wash buffer 5min x3(equ. HRP buffer and TMB to RT)
Mix 1.2ul SA-Poly-HRP(Amersham) in 12 ml HRP buffer
Apply 100ul / well and incubate at RT 30 min
Wash with wash buffer 5min x 3
Wash with wash buffer 5 min x 3
Detection with TMB-substration buffer (Pierce), 100ul / well
Optimize by individual, when color appears
Stop the reaction with 1M H2SO4 50 ul / well
Measureing with Multiskan(Thermo MultiScan) by instruction
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